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ABSTRACT
The recent unraveling of structures of genes for the gonadotro-
pin subunits and gonadotropin receptors has provided reproductive
endocrinologists with new tools to study normal and pathological
functions of the hypothalamic-pituitary-gonadal axis. Rare inac-
tivating mutations that produce distinctive phenotypes of isolated
LH or FSH deficiency have been discovered in gonadotropin sub-
unit genes. In addition, there is a common polymorphism in the
LHb subunit gene with possible clinical significance as a contrib-
uting factor to pathologies of LH-dependent gonadal functions.
Both activating and inactivating mutations have been detected in
the gonadotropin receptor genes, a larger number in the LH re-
ceptor gene, but so far only a few in the gene for the FSH receptor.
These mutations corroborate and extend our knowledge of clinical
consequences of gonadotropin resistance and inappropriate gonad-
otropin action. The information obtained from human mutations
has been complemented by animal models with disrupted or in-
appropriately activated gonadotropin ligand or receptor genes.
These clinical and experimental genetic disease models form a
powerful tool for exploring the physiology and pathophysiology of
gonadotropin function and provide an excellent example of the
power of molecular biological approaches in the study of patho-
genesis of diseases. (Endocrine Reviews 21: 551–583, 2000)
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I. Introduction
THE INFORMATION of genetic causes of human diseasesis accumulating with increasing speed and volume. This
development has become possible through unraveling of struc-
tures and functions of genes present in the human genome, a
task that is almost complete. Although infertility is not con-
ventionally considered an inherited condition, a growing num-
ber of mutations specifically affecting reproductive function
have been detected in humans and characterized in genetically
modified animals. Among single-gene mutations affecting hy-
pothalamic-pituitary-gonadal function (1, 2), we know today
those of the orphan nuclear receptor DAX1, extracellular pro-
tein KAL (anosmin), the receptor of GnRH, the homeodomain
genes HES1 and PROP1, the receptors for estrogen and andro-
gen, the steroidogenic acute regulatory protein (StAR), a num-
ber of steroidogenic enzymes, and finally those of gonadotro-
pins and their receptors, the topic of this review.
Mutations of genes concerned with hypothalamic-pitu-
itary-gonadal function, due to their critical role in the de-
velopment and regulation of reproductive functions, are un-
derstandably very rare and therefore not of major concern
within the clinical practice of infertility treatment. However,
they form today a class of diagnoses that must be taken into
account upon differential diagnostics of aberrant and de-
layed sexual differentiation and development, as well as
infertility. In addition, by displaying distinct phenotypes,
these conditions have turned out to be very elucidating with
regard to the main facets and certain poorly characterized
details of the hormonal control of reproduction. These nat-
urally occurring mutations are often corroborated by genet-
ically manipulated animal models with astonishingly similar
phenotypes to those of the human diseases. The same applies
to the currently known human mutations of gonadotropin
and gonadotropin receptor genes, as well as to their animal
models.
Whereas the hormone ligand mutations that have been
Address reprint requests to: Ilpo Huhtaniemi, Ph.D., Department of
Obstetrics and Gynecology, University of Aberdeen, Scotland, United
Kingdom AB25 32D.
* Partially supported by European Commission Grant BIO 4 CT972022.
0163-769X/00/$03.00/0
Endocrine Reviews 21(5): 551–583
Copyright © 2000 by The Endocrine Society
Printed in U.S.A.
551
 at Medical Library Erasmus MC on November 28, 2006 edrv.endojournals.orgDownloaded from 
found to date usually represent loss-of-function mutations
(homozygotes or compound heterozygotes have a pheno-
type), the receptor mutations can be both of the gain-of-
function (also heterozygotes have a phenotype) and loss-of-
function type. In addition to clear-cut disease-causing
mutations, the genome of all individuals is full of small
structural variations, polymorphisms, which usually are as-
sociated with repeats in noncoding regions of the genome or
point mutations within the genes. They may or may not cause
alterations in gene function or structure of the encoded pro-
tein, and, consequently, often have no clear-cut phenotypic
expression. However, subtle changes in function of the en-
coded protein, with mild phenotypic expression, are also
possible in these cases.
II. Structure-Function Relationships of
Gonadotropins and Gonadotropin Receptors
Together with TSH, the gonadotropins LH, human CG
(hCG), and FSH form the family of glycoprotein hormones.
LH, FSH, and TSH are produced in the pituitary gland, while
the LH homolog hCG originates from the placenta. The mem-
bers of this family of relatively large proteins (molecular
mass, 30–40 kDa) consist of a common a-subunit and a
hormone-specific b-subunit that are associated through non-
covalent interactions. The mature a-subunit consists of 92
amino acid residues and is encoded by a single gene, com-
prising four exons, which is localized on chromosome
6q12.21 (Fig. 1). The a-subunit protein contains 10 cysteines,
which are involved in intrasubunit disulfide linkages and
two N-linked glycosylation sites. Although the b-subunits
confer functional specificity of the hormones, they show con-
siderable amino acid identity, ranging from 32% for the LH-
TSH pair to 83% for the LH-hCG pair (excluding the non-
homologous C-terminal extension of hCG). The b-subunit
genes are located on different chromosomes: the LH/hCGb
gene cluster on chromosome 19q13.32, FSHb on chromosome
11p13, and TSHb on chromosome 1p13. The LH/hCGb gene
cluster consists of one LHb gene and six hCGb genes and
pseudogenes (3). At least five of the hCGb genes are ex-
pressed in choriocarcinoma cells and placenta, but most of
steady-state hCGb mRNAs appear to be transcribed from
genes 3, 5, and 8 (4).
The mature b-subunit proteins contain 12 cysteine pairs
that form six intrasubunit disulfide bridges, two N-linked
glycosylation sites (one in LHb), and range in length from
111–145 amino acid residues. The hCGb gene is thought to
have been recently evolved from the LHb gene through a
frameshift mutation in the last exon of the gene causing
extension of the reading frame (5). Thus, the hCGb protein
is larger than the LHb protein, containing a C-terminal ex-
tension of 29 amino acids, with four additional O-linked
glycosylation sites not present in LHb. This structural dif-
ference explains the longer circulating half-life and higher
biopotency of hCG over LH.
The crystal structure of deglycosylated hCG (6) has re-
vealed that the a-subunit and the b-subunits both contain
a so-called cystine knot structure, similar to some remotely
related signaling molecules such as transforming growth
factor-b (TGFb), nerve growth factor (NGF), and platelet-
derived growth factor (PDGF). Each subunit has elongated
shape with two b-hairpin loops on one side of the central
cystine knot and a long loop on the other side. The non-
covalent interaction between the two subunits is stabilized
by a segment of the b-subunit that extends like a “seat-
belt” around the a-subunit and is “locked” by a disulfide
bridge.
Just as their ligands, the receptors for the glycoprotein
hormones have related structures (Fig. 2). The receptors be-
long to the large family of G protein-coupled receptors,
whose members all have a transmembrane domain that con-
sists of seven-membrane traversing a-helices connected by
three extracellular and three intracellular loops. The glyco-
protein hormone receptors form a separate subgroup within
this large family on the merit of their large extracellular
hormone-binding domain at the N terminus. FSH and TSH
bind to the FSH and TSH receptors, respectively, while LH
and hCG both bind to the same LH receptor. The LH and FSH
receptor genes are located on chromosome 2p21 (7) and
2p21–16, respectively (8, 9), while the TSH receptor is found
on a different chromosome, 14q31 (10, 11). The relationship
of the glycoprotein hormone receptors to the other G protein-
coupled receptors is indicated by their sequence homology
in the C-terminal half of the receptor. This domain, encoded
by a single, last exon, contains the seven-transmembrane
segments and the G protein-coupling domain. The extracel-
lular domain of the glycoprotein hormone receptors is en-
coded by the preceding 9 or 10 exons.
The 59-terminal part of the open reading frame of exon 1
encodes the signal peptide that directs the protein to the
luminal side of the endoplasmic reticulum and eventually to
the extracellular side of the plasma membrane. The amino
acid sequence encoded by the following exons 2–9 (2–10 in
LH receptor) has been shown to confer hormone specificity
and binding to the gonadotropin receptors (12), and it con-
tains a number of so-called leucine-rich repeats, which are
found in a diverse group of proteins (13, 14). The crystal
structure of a ribonuclease inhibitor, which contains a num-
ber of leucine-rich repeat units, revealed a nonglobular, flex-
ible crescent-shaped molecule in which the leucine-rich re-
peats correspond to ba-structural units that may be
responsible for the protein-binding function of ribonuclease
inhibitor. The extracellular domain of the glycoprotein hor-
mone receptors with nine such leucine-rich repeats may have
a similar structure, and this feature was used as an aid in
studies of the interaction of hCG with the LH receptor (15–
17). The leucine-rich repeat units are flanked by motifs that
appear to be structurally stabilized by cysteine disulfide
bridges (17).
In the extracellular domain of the LH and FSH receptors,
a number of potential N-linked glycosylation sites have been
identified. There are six sites in the LH receptor: Asn 99, 174,
195, 291, 299, and 313; and four sites in the FSH receptor: Asn
191, 199, 293, and 318, although the last site is not conserved
among species (Fig. 2; the amino acids in the receptor pro-
teins are numbered by taking the first methionine of the
signal peptide as 1). The role of N-linked glycosylation in
receptor function is not completely elucidated, and some
seemingly contradictory results have been presented. Chem-
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ical deglycosylation of the rat LH receptor, or inhibition of
glycosylation by tunicamycin treatment, did not prevent cor-
rect LH receptor folding, hormone binding, and signal trans-
duction (18, 19). Mutational analysis of the rat LH receptor
revealed a decrease or even complete loss of hormone bind-
ing activity upon elimination of the potential glycosylation
sites at Asn103, Asn178, and Asn199 (equivalent to Asn99,
Asn174, and Asn195 in the human), indicating the presence of
functional carbohydrate chains at these positions in the rat
ovarian LH/hCG receptor (20). Additional studies of the rat
LH receptor using more extensive mutational dissection
showed that all potential consensus glycosylation sites are
N-glycosylated, but also revealed that the deleterious effects
of the mutated N-linked glycosylation sites on rat LH re-
ceptor function result from the amino acid substitutions per
se, and not from absent glycosylation (19). In the case of the
rat FSH receptor, two of the three glycosylation sites (Asn191
and Asn293) are actually glycosylated, and a carbohydrate at
either residue is required for efficient and correct folding of
the receptor (21).
The extracellular ligand-binding domain of the gonado-
tropin receptors is connected to the transmembrane signaling
domain by a hinge region. It is not clear whether this struc-
ture has functions other than serving as a connecting peptide,
although the part of the hinge region closest to the first
transmembrane segment is well conserved between the gly-
coprotein hormone receptors, suggesting a special role. In-
terestingly, in the marmoset monkey, exon 10 of the LH
receptor gene, although present in the genome, is always
completely spliced out from the mature mRNA (22). Exon 10
FIG. 1. Schematic representation of
the human gonadotropin subunit genes.
In the top part of each scheme the gene
structure is depicted. The open bars in-
dicate sequences that do not encode pro-
tein (noncoding). The closed bars indi-
cate the sequences that comprise the
open reading frame. The genes are
drawn to scale. In the bottom part of
each scheme the protein structure is
shown. The signal peptide is indicated
by the shaded bar, while the mature
protein is depicted by the open bar. The
numbers below the protein signify the
start and end of the signal peptide and
the length of the mature protein prod-
uct, taking the first amino acid of the
mature protein as 1. Below the protein
the positions (and number of amino
acid) of the N-linked glycosylation sites
are indicated by inverted triangles and,
in the case of CGb, the O-linked glyco-
sylation sites (circles). The connecting
lines between the coding exons in the
top part of the scheme and the protein
structure in the bottom part serve to
indicate the sections of the protein en-
coded by the respective exon. Note that
the b-genes consist of three exons, and
that the common a-subunit gene is
much larger mainly because of addition
of the first, noncoding exon and long
intron 1. In contrast to the other
b-genes, the first exon of FSHb is non-
coding and exon 3 encodes a long 39-
untranslated region (open bar). The in-
formation shown in this figure is taken
mainly taken from Ref. 3 and GenBank.
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encodes the N-terminal part of the cystine cluster that is
proposed to flank the leucine-rich repeat structure at its C
terminus (17). This cluster has a chemokine-like structure,
indicating an important function in the LH receptor. Nev-
ertheless, the marmoset LH receptor (22) appears to function
normally, suggesting that this cystine motif is not important
in this species for receptor action and may act merely as a
spacer allowing correct location of the extracellular domain
in relation to the transmembrane domain. However, if exon
10 is deleted from the human LH receptor, the transit of the
mutated receptor to the cell membrane is hampered (23), and
the same is found to occur in a naturally occurring human LH
receptor mutation in which the sequence encoding exon 10
is spliced out (Ref. 24; see below, Section V.B).
The transmembrane domain with its seven membrane-
spanning a-helices, connected by three extracellular and
three intracellular loops, is similar to the other members of
the large family of G protein-coupled receptors. Evidence has
been presented that the transmembrane domain is sufficient
for hormone binding (25), but this report has not been sub-
stantiated by other investigators. A molecular model of the
LH receptor has proposed that some parts of the extracellular
loops may function as contact points for the hormone bound
to the extracellular binding domain and/or to this domain
itself, relaying the hormonal signal to the intracellular face of
the receptor (15). Together with the cytoplasmic parts of the
transmembrane a-helices, the intracellular loops and the C-
terminal tail of the receptor form the interaction domain with
G proteins. As with other members of the G protein-coupled
receptor family, the third intracellular loop and the cyto-
plasmic tail are most closely involved in G protein coupling
and in the selectivity of coupling to specific types of G pro-
teins (26, 27).
The LH and FSH receptors are mainly coupled to Gs, the
G protein that activates the various adenylyl cyclase isoen-
zymes, resulting in elevation of intracellular cAMP levels.
Both of these receptors, however, are also able to activate
other signal transduction pathways, and in in vitro experi-
ments with cells isolated from experimental animals (rat,
mouse, porcine) or transfected with LH or FSH receptor
cDNA (human, rat, mouse), increased phosphatidylinositide
turnover, elevated intracellular Ca21, and activation of mi-
togen-activated protein kinases have been found (26, 28–40).
Coupling to Gi proteins has been demonstrated for bovine
and murine LH receptor (28), while the porcine LH receptor
is able to activate Gq/11 and G13 in addition to Gi (32, 41,
FIG. 2. Schematic representation of the human gonadotropin receptor genes. The structure of the genes is depicted in the top of the drawings.
The open bars indicate sections of the exons that encode untranslated regions of the mRNA, while the closed bars indicate those sequences that
encode the protein. Although the genes are not drawn to scale, exons that are grouped in the gene are also drawn grouped. Both genes are at
least 80 kb in size. The relation between the intron/exon structure of the gene and the domains of the protein are indicated by the broken lines.
The horizontally hatched part of the protein indicates the signal peptide, and the cross-hatched bars signify the seven segments of the
transmembrane domain. The numbers below the protein indicate the start and end of the signal peptide and the length of the total protein product
including the signal peptide. The numbered inverted triangles below the protein indicate the positions of N-linked glycosylation sites. Note that
the receptor genes are very similar in structure with the exception of an additional exon 11 in the LH receptor gene (see text). Exon 1 encodes
the signal peptide and a small part of the extracellular domain; the following eight or nine exons encode the rest of the extracellular domain,
including the leucine-rich repeat motifs. In both receptor genes, the final exon is the largest and contains the information for the transmembrane
signal transduction domain. The information shown in this figure is taken mainly from Ref. 8 and GenBank.
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42). Further studies will be necessary to elucidate the identity
of G proteins coupling to the FSH receptor and to unravel
possible species specificity of G protein coupling of either
receptor type. The alternate intracellular pathways are in
most cases activated at higher hormone concentrations than
the cAMP pathway and may depend on high receptor den-
sities (33). Therefore, their physiological relevance often re-
mains unclear, although high serum levels of hCG and LH
during pregnancy and around the time of ovulation, respec-
tively, may make use of them.
Upon hormonal stimulation, the LH and FSH receptors
desensitize, i.e., the hormonal signal is relayed in a less ef-
ficient manner. This process is caused by uncoupling of the
receptor from the intracellular transducing G proteins, and
by internalization of the receptor, resulting in decreased den-
sity of extracellularly exposed hormone binding sites. Most
experiments addressing desensitization mechanisms have
been carried out with rodents, either in vitro with isolated
gonadal cells or in vivo following hormonal stimulation. In-
cubating purified testicular Sertoli (43, 44) or Leydig cells (45,
46) with FSH or LH, respectively, leads to rapid loss of
hormone binding and cAMP response caused by loss of
membrane receptors through internalization of the hormone-
bound receptors. Similar findings have been made with var-
ious ovarian cell models in vitro (47–50). In most experimen-
tal conditions, treatment of animals with LH, hCG, or FSH
results in decreased responses of their testicular (51–53) and
ovarian target cells (54–56). However, these mechanisms are
not operative in all tissues. In the human corpus luteum, LH
receptors or their mRNA are not lost under conditions of
increasing hCG levels (57) or in fetal Leydig cells in the
presence of high levels of placental hCG or increased LH
secretion by the fetal pituitary (58–60).
In addition to the loss of receptors through internaliza-
tion, a reduction in density of gonadotropin membrane
receptors can also be caused by decreased receptor syn-
thesis. In cultured immature rat Sertoli cells, a 4-h incu-
bation with FSH or a cAMP analog causes complete dis-
appearance of FSH receptor mRNA, probably through a
posttranscriptional process involving a change in FSH re-
ceptor mRNA stability (44). Less strong effects of FSH that
did not appear to involve mRNA stability changes were
observed in another study with rat Sertoli cells (61). In
cultured granulosa cells from rat and porcine origin, both
stimulating and inhibitory effects of FSH on FSH receptor
mRNA have been observed (62– 65). However, these ob-
servations may be a reflection of the differentiating actions
of FSH on the granulosa cells, rather than rapid sensiti-
zation or desensitization effects. In similar culture studies
with porcine Leydig cells (66), mouse tumor Leydig cells
(67, 68), and rat granulosa cells (69), LH/hCG caused rapid
LH receptor mRNA loss. Also in the case of the down-
regulation of LH receptor mRNA levels, it remains unclear
whether mRNA stability is involved in all cases.
Agonist-induced phosphorylation of G protein-coupled
receptors by second messenger kinases such as protein
kinase A or by G protein-coupled receptor kinases (GRKs)
leads to receptor uncoupling and internalization through
a process that involves binding of inhibitory proteins (ar-
restins) to the receptor and targeting to clathrin-coated pits
(70, 71). This process has been best studied for the adren-
ergic receptors, but it is also involved in uncoupling and
internalization of the gonadotropin receptors. Both rat LH
and FSH receptors are uncoupled and internalized after
stimulation, and subsequent phosphorylation of the C-
terminal tail [LH receptor (72, 73)] or the first and third
intracellular loops [FSH receptor (74)] has been implicated
to play a role in this process. In vitro coexpression of rat
LH or FSH receptors with several different GRKs or b-
arrestins results in increased uncoupling and internaliza-
tion, demonstrating the involvement of these proteins in
the regulation of gonadotropin receptor function (75–78).
Phosphorylation of the LH and FSH receptors is not al-
ways sufficient or necessary for the desensitization pro-
cesses (42, 79, 80), as is also found for other G protein-
coupled receptors (81, 82). Changes in conformation of the
receptor may also be important (83).
Recently, two more distantly related members of the
glycoprotein hormone receptor family, named LGR4 and
HG38/LGR5, were identified from expressed sequence tag
(EST) databases based on their similarities to the other
family members (84, 85). The most conspicuous difference
between LGR4 and HG38/LGR5 and the other family
members was found to be the addition of an extra eight
leucine-rich repeat in the extracellular domain. LGR4 and
HG38/LGR5, whose ligands and function are as yet un-
known, show a less strict tissue distribution of expression
(LGR4: ovary, testis, adrenal, placenta, thymus, spinal
cord, thyroid; LGR5: muscle, placenta, brain, spinal cord)
than the LH, FSH (ovary, testis), and TSH (thyroid) re-
ceptors (84, 85). Several groups, however, have reported
that the LH receptor gene also is expressed in several
nonclassical gonadotropin target tissues, such as placenta,
brain, adrenal gland, and prostate (86 – 89) and in normal
and malignant breast tissue (90). However, the physio-
logical significance of this “ectopic” LH receptor expres-
sion still remains unclear, since the effects of the absence
of LH receptor function found in patients do not indicate
effects on other tissues than the gonads, although these
observations are limited by the effects of the pseudoher-
maphroditism or amenorrhea found in such cases (see
below).
III. Normal and Pathological Gonadotropin Function
A. During sexual differentiation
The advances in molecular biology techniques have al-
lowed major progression in our knowledge of the regulation
and control of sex differentiation and gonadal function. Sev-
eral of the genes that function at the very basis of the gonadal
development are now known (e.g., WT1, SF1), as well as the
proteins that govern whether a gonad develops in the male
or female direction (e.g., Sry, Sox9, Dax1) (91).
During the first phase of sex differentiation, i.e., commit-
ment of its direction, two testicular hormones come into play,
signaling the direction of gonadal development to other gen-
ital structures of the developing fetus. The Sertoli cell prod-
uct anti-Mu¨llerian hormone (AMH; also known as Mu¨llerian
inhibiting substance, MIS), causes the regression of the an-
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lagen of the female internal genitalia, i.e., the Mu¨llerian ducts,
preventing the development of these female organs in the
male. The growth and differentiation of the male internal
genitalia, which develop from the Wolffian ducts and the
urogenital sinus, is stimulated by the androgen testosterone,
produced by Leydig cells of the fetal testis, and in some target
tissues by 5a-dihydrotestosterone, a metabolite of testoster-
one through conversion by the 5a-reductase enzyme. In the
human fetus, after an initial gonadotropin-independent
phase, this activation of steroidogenesis, as well as Leydig
cell growth and differentiation, is completely dependent on
placental hCG. Although the majority of hCG is secreted to
the maternal circulation, its concentration in fetal blood is
high enough to stimulate fetal testicular steroidogenesis (59).
The role of fetal pituitary gonadotropins in the regulation of
gonadal function in utero is apparently negligible. As will be
elaborated below, male development is largely dependent on
correct hormone production by the fetal and postnatal testis.
In contrast, the fetal ovary is hormonally silent and fetal
differentiation into the female direction appears to be totally
independent of gonadotropins and gonadal function. The
fetal ovary apparently does not express gonadotropin re-
ceptors (92).
A short period of high gonadotropin secretion after birth
in both sexes is probably responsible for the postnatal peak
of testosterone measured in baby boys during the first 3–4
months of postnatal life (93), whereas nothing is known
about its possible effects on the ovary. After this postnatal
peak, gonadotropin secretion is suppressed to very low lev-
els until the advent of puberty. However, pulsatile release of
low levels of gonadotropins, predominately at night, is also
found in prepubertal children (94). The prepubertal testes
apparently have both LH and FSH receptors, since they show
clear testosterone and growth responses to LH/hCG and
FSH, respectively (95, 96). In contrast, no data are available
on the presence of gonadotropin receptors in the prepubertal
ovary. However, also prepubertal ovaries may express go-
nadotropin receptors, since ovarian follicles of girls with a
central activation of the hypothalamus/pituitary start pro-
ducing estrogens.
Puberty can be envisaged as the second phase of sexual
differentiation. Reactivation of the hypothalamic-pituitary-
gonadal axis results in increased secretion of LH and FSH
from the pituitary, with stimulation of the cognate gonadal
target cells. Again, steroid hormone production plays a cen-
tral role in signaling the maturation of gonadal function to
extragonadal tissues. The androgen production of Leydig
cells is now activated by pituitary LH and induces the sec-
ondary sex characteristics of the adult male. Feminization
and attainment of fertility of the female occur under control
of estrogens and progesterone, produced by the stimulated
ovarian follicles and corpus luteum through combined ac-
tions of FSH and LH.
B. Mature function
In the ovary, granulosa cells are the only target cells of FSH
action, thus expressing the FSH receptor, whereas both theca,
stromal, late-stage (luteinizing) granulosa, and luteal cells
contain LH receptors. The known role of FSH in the ovary is
to stimulate follicular maturation, including follicular estro-
gen production through aromatization of androgens. LH
stimulates androgen production in theca cells, thus provid-
ing substrate for granulosa cell estrogen production. LH also
triggers ovulation, and thereafter maintains the progesterone
production of corpus luteum. In the testis, Sertoli cells are the
target of FSH action and Leydig cells are the target of LH
action. The specific role of FSH in testicular function is still
somewhat unclear, but functions such as stimulation of Ser-
toli cell proliferation in the immature testis and maintenance
of qualitatively and quantitatively normal spermatogenesis,
through indirect effects mediated by Sertoli cells, have been
proposed. The role of LH is to stimulate Leydig cell androgen
production and thereby to maintain the endocrine (extra-
testicular) and paracrine (spermatogenic) effects of andro-
gens.
The synthesis and secretion of gonadotropins are under
positive control of the hypothalamic GnRH (GnRH), and
gonadal steroid and peptide (mainly inhibin) hormones exert
negative and positive feedback effects on gonadotropin syn-
thesis and secretion, either directly at the pituitary level or
indirectly via the hypothalamus, mainly by modulating
GnRH secretion. For GnRH to stimulate gonadotropin se-
cretion, it is important that it is released in pulsatile fashion
from the hypothalamus to the hypophysial portal circulation.
This causes pulsatile secretion of gonadotropins, which is
clearer with LH, due to its shorter half-time in circulation.
However, the pulsatile mode of gonadotropin action at the
gonadal level is apparently not important. Recent studies on
male rats, either by follow-up of endogenous LH and tes-
tosterone pulses, or by pulsatile treatment with recombinant
rat LH, demonstrate that gonadal stimulation is achieved by
trains of multiple LH peaks of sufficient size (97, 98). How-
ever, the pulsatility of these effects may not be critical in view
of effective gonadal stimulation by tonic gonadotropin in-
jections in experimental animals and in humans. The impor-
tance of pulsatility in FSH secretion is even less clear, due to
its longer half-life in circulation.
This pituitary-gonadal function remains basically similar
in the female until menopause, after which estrogen pro-
duction ceases in the absence of follicles, and gonadotropin
secretion increases in the absence of ovarian negative feed-
back effects. In the male, there is gradual suppression of
testicular androgen production and reciprocal increase of
gonadotropins upon aging, beyond 50–60 yr of age.
A number of diseases at the hypothalamic and pituitary
levels can impair the synthesis and secretion of gonadotro-
pins. Aberrations in the hypothalamic regulation of gonad-
otropin synthesis, of which the best example is the absence
of GnRH neurons, can result in Kallmann’s syndrome. This
syndrome is due to disturbed migration of the GnRH neu-
rons from the olfactory placode to their final location in the
hypothalamus. This migration of GnRH neurons is disturbed
in the most common X-linked form of Kallmann’s syndrome
(hypogonadotropic hypogonadism and anosmia) through
mutation in the gene of an extracellular matrix protein, anos-
min, resulting in disturbance in development of olfactory
bulbs and tracts (99). The other causes of abnormally low
gonadotropin secretion include craniopharyngioma and a
variety of other tumors, infiltrative diseases (e.g., sarcoid-
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osis), trauma, vascular disease, radiation therapy, pituitary
infarction, metabolic diseases (e.g., hemochromatosis), and
functional causes such as stress and anorexia nervosa (100,
101). Pathologically increased levels of gonadotropins are
observed in connection with paraneoplastic gonadotropin
secretion, central precocious puberty, and primary hypogo-
nadism (100, 101). We can also include in this category hy-
perthyroidism associated with pregnancy and trophoblastic
tumors, where the highly elevated levels of hCG, due to
structural similarity of LH/hCG, TSH, and their cognate
receptors, are able to stimulate thyroid function by binding
to the TSH receptor (102). More detailed discussion of these
conditions is beyond the scope of this review.
A rare condition of suppressed gonadotropin action is
caused by disturbance of gonadotropin glycosylation. This
step of gonadotropin synthesis normally occurs through ac-
tion of a group of specific enzymes, which in rare cases are
inactivated by mutations. Although the actions of the gly-
cosylation enzymes are not specific for gonadotropins, their
mutations nevertheless appear to influence the formation of
functionally competent glycoprotein hormones. The condi-
tion is called carbohydrate-deficient glycoprotein syndrome,
where several different autosomal recessive enzyme defi-
ciencies can result in incomplete glycosylation of plasma
proteins (103). The syndrome appears to cause hypergo-
nadotropic hypogonadism in women, where the high circu-
lating levels of immunoreactive FSH have been found to have
very low bioactivity (104–106). Male patients with this syn-
drome virilize at puberty but display suppressed testicular
volume. LH levels and LH action seem to be only marginally,
or not at all, affected in the subjects. This syndrome empha-
sizes the importance of proper glycosylation of gonadotro-
pins for their bioactivity. Although it remains unclear why
FSH is more affected than LH, the phenotypic expression of
this disease is reminiscent of genetic inactivation of FSH or
its receptor (see below).
In addition to the genetic alterations of gonadotropin re-
ceptor genes, the topic of the present review, there are also
other causes for the end-organ gonadotropin resistance, i.e.,
hypergonadotropic hypogonadism. The apparent causes in-
clude anatomical aberrations of gonadal development and
structure in various forms of gonadal dysgenesis and agen-
esis (107). The most common form of ovarian dysgenesis is
Turner’s syndrome (45, XO), The other forms include diag-
noses such as pure gonadal dysgenesis, ovarian steroido-
genic enzyme defects, and premature ovarian failure, but
their exact pathogenesis often remains open. Testicular re-
sistance to gonadotropins can be caused by various devel-
opmental abnormalities. The most common chromosomal
aberrations are Klinefelter’s (XXY) and XX male syndromes,
while the other diagnoses include various forms of idiopathic
and acquired arrest of spermatogenesis, acquired immuno-
deficiency syndrome (AIDS), various neurological diseases,
trisomy 21, effects of drugs, radiation, and environmental
toxins, autoimmunity, and a number of systemic diseases
(108). Gonadotropin resistance of both sexes is also possible,
if there are defects in gonadal actions of other circulating
hormones or of para- or autocrine effectors (109). However,
distinct clinical conditions with disturbances in these func-
tions are not yet known.
IV. Mutations in Human Gonadotropin
Subunit Genes
A. Common a-subunit
Although there are several reports on restriction fragment
length polymorphisms (RFLP) of the human glycoprotein
hormone common a-subunit gene (110–113), none of them
appear to influence the encoded amino acid sequence. Some
studies (112, 114, 115), though not all (116), report that par-
ticular common a genotypes are disproportionately repre-
sented in DNA derived from trophoblastic malignancies.
Paired normal and tumorous tissues from the same subject
showed similar RFLP patterns, suggesting that particular
common a alleles predispose toward a variety of neoplasias,
rather than represent somatic mutations in tumors (115).
How exactly common a-polymorphism is related to tumor-
igenesis remains obscure. It could be linked to mutation of
a neighboring gene with clear causal relationship to the ma-
lignancy, although it may also represent a spurious associ-
ation.
The only genetic alteration so far reported in the a-subunit
protein is a single Glu56Ala amino acid substitution in a-
subunit ectopically secreted by a human carcinoma (Table 1)
(117). This mutated protein failed to associate with the b-
subunit and appeared to have significantly higher mol wt
than the native a-subunit. It was proposed that the detected
mutation causes altered tertiary structure, self-dimerization,
or altered glycosylation, which could then be responsible for
the ectopic subunit’s increased size and failure to dimerize
with LHb.
The lack of proven germ line mutations in the a-subunit
gene could mean that such changes are lethal. In addition to
gonadotropins, they would also affect the formation of CG
and TSH. The fact that mice with targeted disruption of the
common a-gene are viable (128) (see below) speaks against
this possibility. However, the mouse, not producing CG, may
not be an adequate model for the human in this respect. The
question about possible presence of common a-mutations
and their phenotypic expression in the human thus remains
open.
B. Mutations of the LHb subunit
The only true human mutation of the LHb gene causing
total functional inactivation is that described by Weiss et al.
(118) (Table 1). The proband was a male, who presented with
delayed puberty at the age of 17 yr. He was a member of a
previously identified kindred with several infertile men (129)
and had low testosterone and high immunoreactive LH se-
rum concentrations. His testosterone secretion responded
normally to exogenous LH and hCG, but in an in vitro bio-
assay serum LH was found to be devoid of bioactivity (130).
These findings, together with the occurrence of infertility in
three maternal uncles (with slightly lowered testosterone
and increased LH) and a family history of consanguinity,
suggested that the man had an inherited defect in the struc-
ture of LH, although his mother and sister had no symptoms
of reproductive inadequacy. After two years of testosterone
treatment, no sign of spontaneous puberty was seen after
withdrawal of the treatment. Testicular biopsy revealed ar-
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rest of spermatogenesis and absence of Leydig cells. Long-
term treatment with hCG resulted in testicular enlargement,
normal virilization, and onset of spermatogenesis.
Upon sequencing of the LHb subunit gene of the subject,
a homozygous A-to-G missense mutation was found in
codon 54, causing a Glu-to-Arg substitution (118). The
subject’s mother, sister, and three uncles were found to be
heterozygous for the same mutation. A gene conversion
whereby sequences from the CGb gene are exchanged
with or incorporated in the LHb gene was excluded, which
indicated that the alteration in LHb structure represented
a spontaneous germ line mutation. Coexpression of the
mutated LHb gene with normal a-subunit gene in CHO
cells resulted in formation of immunoreactive LH a/b
heterodimers, with no activity in RRA, i.e., the mutated
hormone was devoid of biological activity because of in-
ability to bind to the LH receptor. In the heterozygous
family members, as expected, the bioactivity of LH was
reduced in relation to immunoreactivity, since half of their
LHb was encoded by the mutated gene.
This rare case clarifies some points about the develop-
mental role of pituitary LH. Since the proband was appar-
ently normally masculinized at birth with descended testes,
pituitary LH is not needed for the stimulation of testicular
testosterone production in utero. Indeed, testosterone pro-
duction is initiated autonomously, but becomes subse-
quently dependent on placental hCG (58, 59), and fetal pi-
tuitary LH apparently plays no role in regulation of fetal
testicular function. However, the endocrine function of the
postnatal testes is critically dependent on pituitary LH se-
cretion, as was demonstrated by the total absence of spon-
taneous puberty in this subject lacking bioactive LH. It is
intriguing that the heterozygous male family members had
impaired steroidogenesis and high incidence of infertility
despite normal pubertal masculinization. However, since the
proband’s father was an obligate heterozygote, the impor-
tance of the heterozygozity for testicular function remains
open. The heterozygous women, including the proband’s
mother, were apparently free of symptoms. It is curious that
no other human subjects homozygous for this type of mu-
tation have yet been detected. The female phenotype would
probably resemble those with inactivating LH receptor mu-
tation (see below). Comparison of these two conditions
would elucidate the role of intrauterine LH/hCG action, if
any, in ovarian development and function.
C. Genetic variants of LHb subunit
Sequence variability of the LHb chain was observed in
early reports on chemical sequencing of this protein (131),
but the existence of polymorphic alleles of the LHb gene has
only been recently recognized.
Upon testing the applicability of various monoclonal
antibodies (Mabs) for the detection of LH, using the immuno-
fluorometric assay (IFMA) principle, Pettersson and col-
leagues (132–134) described a healthy woman with two
children, whose LH was undetectable using a Mab directed
against an antigenic epitope present only in the intact LH
a/b dimer (assay 1). The woman’s LH bioactivity and the
ratio of bioactivity to immunoreactivity (using a subunit-
specific IFMA for immunoreactive LH measurement, assay
2) were normal and in accordance with her normal fertility.
Since her TSH and FSH levels were also normal, indicating
no abnormalities in the common a-subunit gene, the LHb
gene was sequenced (119, 135). The LHb gene of the subject
was found to represent a genetic variant (V) allele of the LHb
gene, with two missense mutations: Trp8Arg (TGG -. CGG)
and Ile15Thr (ATC-.ACC) [Table 1 and Fig. 3 (119, 135)].
Recently, the same LHb allele was reported from Japan (120,
136) in female patients with infertility, and their LH likewise
was unmeasurable with an immunometric assay kit using
two Mabs. There is a complete linkage of the two mutations
in all samples so far analyzed from various populations (135).
In addition to RFLP and allele-specific oligonucleotide
hybridization (135), IFMA assays offer a quick and robust
way to detect the V-LHb allele. By calculating the ratio of LH
measured by IFMA assay 1/assay 2 (see above), the popu-
lation can be subdivided into three groups: normal ratio [1–2,
homozygotes for wild-type (WT) LHb], low ratio (0.5–0-75,
heterozygotes) and zero ratio (close to 0, homozygotes for
V-LHb) (Fig. 4). It was found that in the normal Finnish
population, the carrier frequency of the V-LHb allele was
about 28% (137).
The Ile15Thr mutation in V-LHb introduces an extra gly-
TABLE 1. The currently known mutations and polymorphisms, altering protein structure, that have been detected in gonadotropin
subunit genes
Gene Location Type Base change Amino acid change Effect at protein level Ref.
Common a Exon 3 Missense CA239G3CCGa Glu56Ala No association with b-subunit (117)
LHb Exon 3 Missense GG221C3GAC Glu54Arg Absent bioactivity (118)
Normal immunoreactivity
Exon 2 Two missense mutations
in the same allele
T82GG3CGG Trp8Arg Poorly detected by a/b specific
antibodies
(119,120)
AT104C3ACC Ile15Thr Increased in vitro bioactivity
Decreased circulatory T1/2
Exon 3 Missense A364GT3GGT Ser102Gly Slightly elevated in vitro
bioactivity
(121)
CGb Exon 3 Missense G295TG3ATG Val79Met Inefficient assembly with
common a
(122)
FSHb Exon 3 2-bp Deletion/premature
STOP codon
GTG3GX236,237 STOP87 No bioactivity or immunoreactivity (123–125)
Exon 3 Missense TG206T3GGT Cys51Gly No bio- or immunoreactivity (126)
Exon 3 Missense T298GT3CGT Cys82Arg No bioactivity or immunoreactivity (127)
a Apparently a somatic mutation in tumor.
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cosylation signal (Asn-X-Ser/Thr) into the LHb chain, which
apparently adds a second oligosaccharide side chain to Asn13
of the V-LHb protein. The same structure is present in the
hCGb-chain (Fig. 3) where Asn13 is glycosylated (138). Sug-
anuma et al. (139) demonstrated with recombinant human
V-LH molecules, possessing either of the two mutations, that
Asn13 carries an extra carbohydrate side chain, and that the
Trp8Arg mutation is mainly responsible for the altered im-
munoreactivity of v-LH.
The worldwide frequency of the V-LHb gene has been
extensively studied (135, 140–144), and it appears to be high-
est in the Northern European populations (allelic fre-
quency . 10%) and, interestingly, in Australian aboriginals
(28.3%), whereas lower frequencies are found in Asian pop-
ulations and American Indians (2.5–5%). In all ethnic groups
with a representative number of observations, the WT and
V-LHb alleles are in Hardy-Weinberg equilibrium. It is cu-
rious that such a high variability of carrier frequency as from
0 to .50% (allelic frequency from 0 to 28.3%) can be found
for V-LHb. It is tempting to speculate that V-LH has, in
prehistoric times, offered reproductive advantage for pop-
ulations living in untoward external conditions. It also seems
that its correlation with various pathologies related to pitu-
itary-gonadal function varies between different populations,
and their penetrance is apparently dependent on the genetic
background (see below).
Due to its high frequency, more detailed studies on func-
tional effects of V-LH were warranted. Both serum V-LH
(137) and its recombinant form (139) are more active than
WT-LH in in vitro bioassay, with lower ED50 and about 20%
higher maximum effect. In contrast, V-LH shows a clearly
shorter half-life in circulation than WT-LH (26 vs. 48 min). As
expected, the pulsatile pattern of LH secretion is not altered
in carriers of the V-LHb allele (137). This leaves it somewhat
open, whether the overall in vivo activity of V-LH is higher or
lower than that of WT-LH. V-LH thus seems to be more active
at the receptor site but the duration of its action is shorter. Most
of the clinical observations indicate that V-LH represents a
functionally weaker form of the hormone (see below).
To explain how a hormone with significantly shortened
circulatory half-life can maintain grossly normal gonadal
function, we hypothesized that its synthesis may be com-
pensatorily enhanced. This would require alterations in the
promoter function of the V-LHb gene. Indeed, when the
V-LHb promoter was sequenced, a total of eight point mu-
tations were detected within the first 650 nucleotides of its
59-flanking sequence, and they always segregated with the
two point mutations detected earlier in its coding sequence
(145). The mutant promoter appeared about 50% more active
than the WT promoter upon cell transfection studies, and it
also displayed some qualitative differences in response to
various hormonal stimuli. Hence, these findings demon-
strated an intriguing evolutionary principle: if the function
of a protein is altered through mutation in its gene, the
change may be compensated for by additional mutations in
its regulatory sequences that bring about opposite changes in
synthesis of the mutated gene product.
Whether any particular phenotype(s) are related to V-LH
is still somewhat unclear. It is also possible that both hetero-
and homozygosity for the variant allele could give rise to
different phenotypes. If we presume that V-LH represents a
potent but short-acting form of LH, and WT-LH a less potent
but long-acting form, a combination of both LH forms, as
occurs in heterozygotes, could bring about different overall
LH action than either of the forms alone. These qualitative
differences between actions of WT and V-LH, including dif-
ferences in their promoter function, provide the strongest
evidence for possible phenotypic effects of V-LH. If the dif-
ferences between the two hormone forms were only quan-
titative, then they could be fully compensated for by alter-
ations in feedback regulation of LH secretion.
The first reports from Japan described V-LHb homozy-
gosity with recurrent spontaneous abortions (136), menstrual
irregularities with infertility (120), and polycystic ovarian
syndrome (PCOS) (120, 146). Subsequently, various distur-
bances in pituitary-ovarian function have also been found in
V-LHb heterozygotes (143, 147). Clear findings have not been
made in Caucasian populations (137, 148–150), although in
a study on predominately Jewish subjects from the Boston
(Massachusetts) area, heterozygous women for V-LHb had
a history of frequent use of infertility treatments (D. Cramer
and I. Huhtaniemi, unpublished study). In Finland, no as-
sociation of V-LH was found in women with history of re-
current miscarriages (151).
Heterozygous women for the V-LHb allele have higher
levels of serum testosterone, estradiol, and sex-hormone-
binding globulin (148), which indicates differences in ovar-
ian LH action between WT- and V-LH. In a multicenter study
from Finland, the United Kingdom, The Netherlands, and
the United States, with a total of 1,466 subjects, of whom 363
had PCOS and 79 polycystic ovaries without other symptoms
of PCOS, it was found that the V-LHb frequency was 5- to
7-fold lower in obese PCOS subjects compared with that in
other groups, i.e., lean PCOS subjects and lean and obese
controls (2–4.5% vs. 10.3–33.3%, P , 0.05) (149). Thus, V-LH
may protect obese women from developing symptomatic
PCOS, which indicates that the more powerful WT-LH in-
FIG. 3. Structural comparison of WT LHb, the common LHb variant,
and hCGb. The first 20 amino-terminal amino acids in the b-subunits
of WT and variant (VAR) LH, as well as of hCG, are depicted. The large
shaded boxes indicate the positions of the two mutated amino acids
in variant LHb, and the additional amino acids, differing in hCGb
from LHb, are also boxed. The glycosylation signal Asn-Ala-Thr in
LH-VAR-b and hCGb is underlined.
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duces the pathological ovarian responses. However, this
finding was not corroborated in the UK population, despite
similar diagnostic criteria (148, 149). This is in keeping with
the multifactorial pathogenesis of PCOS (152) and empha-
sizes that its pathogenesis in different populations may vary
according to genetic background. Even though V-LH may
not be directly related to PCOS, determination of V-LH may
improve the prediction of risk of PCOS, especially in obese
women. Its high frequency in various populations must be
kept in mind because many widely used immunoassay re-
agents do not detect this LH form. One diagnostic criterion
for PCOS, the elevated LH/FSH ratio, may remain undetec-
ted if such an LH assay is used, as has been emphasized
recently (153). Other phenotypic associations with V-LH in-
clude the delayed tempo of pubertal progression in boys
heterozygous for V-LHb (154), and in elderly men, it was
more common in those with low testosterone and high LH
concentrations (150). However, larger numbers of observa-
tions from various ethnic groups are needed to resolve the
role of V-LH in pathologies of gonadal function and infer-
tility.
Hence, there is some evidence for association of V-LH, as
a protective or predisposing factor, with various pathologies
of LH action. Since findings in various ethnic groups do not
always agree, the overall genetic background of the popu-
lation may be important for the phenotypic expression and
penetrance of this relatively mild polymorphic alteration in
structure and function of the LH molecule. V-LH may thus
be an example of influence of genetic heterogeneity on re-
productive functions. Additional polymorphisms affecting
reproductive endocrine functions are likely to be found. In-
terestingly, another polymorphism of LHb, detected recently
(Ser102Gly) in Singapore, has also been implicated in female
infertility (155).
D. hCGb subunit
Several polymorphisms have been detected in the hCGb/
LHb gene complex by RFLP analysis (156, 157), but whether
they result in sequence differences in LH or hCG has not been
studied in detail. Layman et al. (157) were unable to detect
large deletions or duplications of the hCGb/LHb gene com-
plex by genomic Southern blotting in patients with suspected
disorders of hCG production, such as recurrent abortion,
primary unexplained infertility, and gestational trophoblas-
tic neoplasia. A very recent study (122) showed that of the six
hCGb genes present in the human genome, the one most
highly expressed, number 5 (158), is highly conserved. Al-
together six polymorphisms were detected in this gene in a
random population, and they were, with the exception of
one, either silent or located in introns. An A-to-G transition
in exon 3 of hCG gene 5 was found to alter the amino acid:
Val79 Met (Table 1). When the mutated b-subunit was coex-
pressed with the common a-subunit gene in CHO cells, the
assembly of the two subunits was found to be inefficient,
although those dimers that did form had normal bioactivity.
This mutation was found in 4.2% of randomly chosen healthy
subjects, but only in heterozygous form. A limited search in
subjects with infertility (n 5 41) yielded one additional silent
mutation, but the above mentioned amino acid change was
not found in this population. This may be due to the limited
sample size or to the possibility that the mutation is embry-
onic-lethal because of insufficient production of biologically
active hCG. Whether the intronic mutations detected were
truly silent, or affected the rate of transcription or mRNA
splicing, remains to be studied.
E. FSHb subunit
A total of five subjects (three women and two men) with
different inactivating mutations of the FSHb gene have so far
been described in the literature (Table 1). The first mutation
reported was a homozygous 2-bp deletion in codon 61 (Val61)
of the FSHb gene in a woman suffering from primary
amenorrhea and infertility (123). The mutation gave rise to
a completely altered amino acid sequence between codons 61
and 86 of the FSHb chain, which was followed by a prema-
ture stop codon, and lack of translation of amino acids 87–
FIG. 4. Occurrence of WT and variant
LHb alleles in the Finnish population.
The distribution of 249 normal Finnish
subjects into the normal (WT, f), low
(heterozygote, F), and zero (homozy-
gote, ) ratio groups according to the
results of the ratios of LH measured by
assay 1 (measuring only WT-LH) and
assay 2 (measuring equally WT and
V-LH). The LH level measured by assay
2 is shown on the abscissa. As no sex
differences were detected, the male and
female data are compiled. [Reproduced
with permission from: A. M. Haavisto et
al.: J Clin Endocrinol Metab 80:1257–
1263, 2000 (137). © The Endocrine So-
ciety.]
560 THEMMEN AND HUHTANIEMI Vol. 21, No. 5
 at Medical Library Erasmus MC on November 28, 2006 edrv.endojournals.orgDownloaded from 
111. Consequently, the translated FSHb protein was trun-
cated and unable to associate with common a-subunit to
form bioactive or immunoreactive a/b-dimers. The affected
woman had apparently had normal adrenarche, but no men-
arche or telarche. Treatment of the patient with exogenous
FSH resulted in follicular maturation, ovulation, and suc-
cessful pregnancy. Her mother, heterozygous for the muta-
tion, had suffered from menstrual irregularity and infertility,
but these symptoms were unlikely related to the mutation,
since the heterozygous relatives of other similar patients
have been reported to be free of symptoms (see below).
The second case of inactivating FSHb mutation was also
a female with similar phenotype, i.e., primary amenorrhea
and poorly developed secondary sex characteristics (126).
She had undetectable serum FSH and estradiol, high LH, and
absent FSH response to GnRH stimulation test. Upon DNA
sequencing, she appeared to be a compound heterozygote for
two mutations in the FSHb subunit gene. One was the same
as the mutation described by Matthews et al. (123), and the
other was a missense T-to-G mutation, causing a Cys51-
to-Gly transition in the mature FSHb protein. Cells trans-
fected with the FSHb gene carrying this mutation failed to
produce immunoreactive FSH, apparently because of the
loss of a cysteine critical for formation of proper disulfide
bonds, as well as for synthesis and secretion of the hormone.
No symptoms were found in the relatives heterozygous for
either of the two FSHb mutations of the proband, suggesting
that one intact FSHb gene is sufficient to maintain function-
ally adequate FSH secretion.
In a third female patient with isolated FSH deficiency, re-
ported earlier (159), the cause was originally suggested to be
due to circulating FSH antibodies (160). However, the molec-
ular pathogenesis of this case was recently “re-revisited,” and
it was found to be due to the same homozygous 2-bp deletion
as that of the first detected FSHb mutation (124). The FSH
antibodies apparently developed in response to treatment with
urinary gonadotropins (161), which were recognized as foreign
protein by the patient’s immune system.
The female cases with FSHb inactivation are in good agree-
ment and demonstrate that FSH is necessary for normal
follicular development, ovulation, and fertility. Likewise,
pubertal development is hampered in the absence of suffi-
cient numbers of later stage follicles to harbor the granulosa
cells needed for adequate estrogen production. As will be
described below, this phenotype is practically identical to
that caused by inactivating FSH receptor mutation.
Very recently, two men with FSHb mutations have been
described (125, 127, 162). The report from Sweden by Lind-
stedt et al. (127, 162) described a 32-yr-old man of Serbian
origin with azoospermia and normal puberty, but with se-
lective absence of FSH. The LH-testosterone axis of the pa-
tient was apparently normal. Genetic analysis demonstrated
a homozygous T-to-C mutation, predicting a Cys82-to-Arg
substitution in the FSHb protein. The second male, described
from Israel (125), was an 18-yr-old man with slightly delayed
puberty, small testes, azoospermia, and plasma FSH con-
centration below 0.5 IU/liter. Conspicuously, his testoster-
one level was low (4.5 nmol/liter) and LH high (24.5 IU/
liter). Upon DNA sequencing, the same homozygous 2-bp
deletion in codon 61 was found as reported before with the
female patients (123, 124, 126). It was postulated, on the basis
of studies on hCG biosynthesis (6, 163), that in the Cys82Arg
mutation, elimination of cysteine would result in inability to
form the first intramolecular disulfide bond of FSHb. This
would then result in abnormal tertiary structure during
FSHb synthesis, with extensive intracellular degradation of
the products, inability to associate with common a-subunit,
defective glycosylation, and finally inability to form biolog-
ically active hormone.
As will be elaborated below, the phenotypes of women
with inactivating FSHb and FSH receptor mutations, as well
as the female knockout mice for FSH ligand and receptor, are
in perfect agreement. However, there is an apparent dis-
crepancy between phenotypes of men with inactivating
FSHb and FSH receptor mutations, which still leaves open
the final word about the role of FSH in testicular function.
Since the number of males with FSHb mutation so far re-
ported is only two, and that of men with FSH receptor mu-
tation five (164), the information about the role of FSH in the
male that can be obtained from earlier descriptions of men
with idiopathic isolated FSH deficiency can be valuable.
These studies were done at the time when genetic diagnostics
was not yet available. Some of the subjects with “isolated
FSH deficiency” had associated disorders, such as cryp-
torchidism, hypospadias, omphalocele, deafness, the olfac-
tory-genital dysplasia syndrome, chromosomal alterations,
autoimmunity, or short stature (160, 165–168), and therefore
such patients may not be representative of truly isolated FSH
deficiency. However, many of them seem to fulfill the diag-
nostic criteria. Those reported in full-length articles are sum-
marized in Table 2, together with the two males with genetic
proof of FSHb mutation. In addition, one abstract exists on
isolated FSH deficiency in a male (169).
A problem of the early studies, in addition to the lack of
genetic information on structure of the FSHb gene, is the
suboptimal specificity and sensitivity of the FSH assays
available, for which reason the real level of the low FSH
concentrations remains unclear. This is partly compensated
for by data on absent or subnormal FSH response to GnRH
or clomiphene stimulation, indicating genuine FSH defi-
ciency. Of the nine men presented in Table 2, two had evi-
dence of prior fertility and had normal sperm counts with
poor motility and morphology. Four men had severe oligo-
zoospermia, and three were azoospermic. Testis biopsies
displayed variable types of spermatogenic arrest, and the
testis sizes varied from small to normal. Taken together, the
phenotypic array of these men is very similar to the recently
reported five men with inactivating FSH receptor mutation
(164), displaying slightly to severely impaired spermatogen-
esis, but no azoospermia or obligatory infertility. In the ab-
sence of genetic data, one can naturally question the extent
of FSH suppression in the men with the mildest phenotypes.
However, they strengthen the sparse genetically verified
data on at least some degree of spermatogenesis in the ab-
sence of FSH.
On the other hand, the two men with documented FSHb
mutations (see above) were possibly only detected because
of their azoospermia and/or delayed puberty. The Swedish
patient, unlike some other FSH-deficient men (173), was re-
sistant to FSH treatments for periods of 120 and 210 days
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(162), which may indicate additional contributing factor(s) to
his azoospermia. The Israeli patient, in addition, had Leydig
cell hypofunction, not demonstrated in any of the other FSH-
deficient subjects, or those with FSH receptor defect (164),
indicating the likelihood of an additional FSH-independent
pathology of his testicular function.
In summary, the majority of information available indi-
cates that FSH action per se is not mandatory for the pubertal
initiation of spermatogenesis and fertility. However, quali-
tatively and quantitatively fully normal spermatogenesis ap-
parently needs FSH action. The phenotype of men with de-
fective FSH action varies from severe to mild impairment of
spermatogenesis, in the face of apparently normal Leydig cell
function. The azoospermia found in some of the men may be
due to additional contributing factors, and not to truly iso-
lated FSH deficiency. However, it is apparent that additional
cases of genetically proven FSH deficiency are needed, before
the existing discrepancy between phenotypes of the ligand
and receptor deficiency, as well as the animal models with
disrupted FSHb and FSH receptor genes (see below), can be
resolved. At the moment, it may be warranted to state that
treatment of men with idiopathic oligozoospermia and nor-
mal to elevated FSH concentration with FSH has no scientific
basis, and that prospects of a male contraceptive method
based on inhibition of FSH secretion or action are not prom-
ising.
V. Mutations in Human Gonadotropin
Receptor Genes
In both LH and FSH receptor genes, activating and inac-
tivating mutations have been identified with very different
phenotypic effects. In the case of loss of function, it can be
expected that the inactivating gene mutations range from
missense changes of single amino acid residues, small dele-
tions or insertions, frameshift mutations, and nonsense mu-
tations that cause receptor truncation, to deletions of large
parts of the receptor gene. Inactivating receptor gene muta-
tions are found in homozygous or compound heterozygous
states and the syndromes that are caused by these gene
alterations follow a recessive pattern of inheritance. In con-
trast, activating mutations are much more limited in their
character or position in the receptor gene. Actually, all ac-
tivating receptor mutations in the gonadotropin receptors
have been identified in the exon that encodes a small extra-
cellular extension, the complete transmembrane domain of
the receptor, and its intracellular C terminal tail (exon 11 in
the LH receptor and exon 10 in the FSH receptor; see Fig. 2).
Maps of the currently known LH and FSH receptor muta-
tions are presented in Figs. 5 and 6.
A. Activating mutations in the LH receptor
Activating mutations in the LH receptor gene were the first
to be identified (175, 176). In the early 1980s, a unique form
of pituitary-independent precocious puberty was described
(177–179), characterized by symmetric testicular enlarge-
ment before 3 or 4 yr of age, increased testosterone levels, and
low gonadotropins with prepubertal response to GnRH chal-
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(FMPP) showed an autosomal dominant pattern of inheri-
tance, and a majority of cases of familial male sexual pre-
cocity appeared to belong to this syndrome (180). The au-
tonomous hypersecretion of testosterone could not be
explained by increased gonadotropins since no immunore-
activity of these hormones could be identified in the patients’
serum (178, 181, 182), although some evidence was presented
of a factor in the serum of these boys that could stimulate
monkey Leydig cells (183). Two groups demonstrated that
these familial cases of LH-independent precocious puberty
in boys were caused by mutations resulting in single amino
acid changes in the LH receptor protein (175, 176). In vitro
studies with the a-1B adrenergic receptor had shown that
changing a single alanine residue in the third intracellular
loop to any other amino acid caused partial activation of the
phosphoinositide pathway in the absence of ligand (184). In
addition, mutations in the mouse MSH receptor gene had
been described that caused dominant fur-color traits as a
result of constitutive adenylyl cyclase activation (185). In-
deed, in keeping with the hypothesis, the first mutations of
the LH receptor were identified in the sixth transmembrane
segment (TM6) and the flanking third intracellular loop (IL3),
indicating, as had been found for other G protein-coupled
receptors, that this region of the transmembrane domain was
important for G protein coupling (Fig. 5 and Table 3).
Using in vitro transfection experiments, the mutant LH
receptor proteins were found to increase adenylyl cyclase
activity in the absence of added ligand (hCG or LH) (176,
204), as measured by increased cAMP levels or by elevated
luciferase activity when a reporter plasmid was cotrans-
fected, containing six cAMP-response elements in front of the
luciferase cDNA (Fig. 7) (208). Expression of mutant LH
receptor molecules in the mouse Leydig tumor cell line
MA-10 (227) resulted in increased cholesterol side-chain
cleaving enzyme activity, as determined by the elevated lev-
els of basal and hCG-stimulated pregnenolone production
(228). Although these experiments do not provide formal
proof that the LH receptor mutations cause precocious pu-
berty, the transfected MA-10 cells in part mimic the situation
in the Leydig cells of an FMPP patient, since in both situa-
tions WT and mutant LH receptor alleles are expressed.
Now that more activating LH receptor mutations have
been identified, it can be seen that TM6 and the third intra-
cellular loop are indeed the mutational hot spot of these
alterations, although amino acid changes have been found in
the other transmembrane segments as well, with the excep-
tion of TM4 and TM7 (Fig. 5). No activating mutations have
been found in the other exons of the LH receptor gene that
encode the signal peptide, extracellular hormone binding
domain, and hinge region. Although exons 1–10 have not
been investigated in all FMPP patients, it appears that in
those patients in which no exon 11 mutations could be iden-
FIG. 5. Mutations in the LH receptor
protein. Schematic structure of the LH
receptor protein and localization of the
inactivating (open squares) and activat-
ing (filled circles) mutations currently
known in the human LH receptor. The
short lines across the amino acid chain
separate the 11 exons. For references,
see Table 3.
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tified, most likely other causes of LH-independent preco-
cious puberty are operative (208). However, the finding of an
activating mutation in the extracellular domain of the TSH
receptor protein (229, 230) indicates that also for the gonad-
otropin receptors such mutations cannot be excluded, al-
though they may be rare (231). Their probable scarcity sup-
ports the notion that in the glycoprotein hormone receptors,
the function of hormone binding and signal transduction are
separated. Mutations in the extracellular domain may in-
crease the affinity of the receptor for the hormone but are
probably without effect, since the increased sensitivity of the
receptor would result in a negative feedback response of the
pituitary, lowering ligand (LH or FSH) secretion and, as a
result, the receptor would still be inactive in the absence of
ligand. Only in those mutant receptors that show increased
activity in the absence of hormone does the negative feed-
back action not play a role.
Comparison of the hCG dose-response activity of the re-
ceptor mutants and the WT-LH receptor reveals that, in
many cases, the mutant LH receptor molecules display a
lower response to a maximal stimulatory dose of hCG than
the WT receptor (see e.g., Refs. 204, 206, and 216). A decreased
number of plasma membrane binding sites in cells express-
ing the mutant receptor molecules may be the reason for such
a decrease (27, 190, 205, 210, 211, 213). A low number of cell
surface expression may be caused by mutational effects on
posttranslational modification and transport of the LH re-
ceptor protein (232) or increased internalization of the acti-
vated receptors (83, 233–235). However, a clear correlation
between number of binding sites and maximal response is
not always present. Comparing WT and two mutant LH
receptors, Yano et al. (211) found that although both mutant
receptors showed similar maximal responses to hCG as the
WT LH receptor, one mutant (Ala572Val) displayed 3-fold
less cell surface binding than the other mutant receptor
(Asp578Gly). Similar discrepancy between binding and max-
imal activity was found in a study of the effect of the Ile575Leu
mutation on LH receptor function (190). In keeping with the
separated function of binding and signal transduction in the
gonadotropin receptors, in almost all cases the affinity of the
mutant receptors for the hormone remains unchanged (190,
209, 210, 213).
The Asp578Gly transition in the LH receptor protein is the
most frequently observed amino acid change in FMPP pa-
tients (176, 206), and it appears that there is a strong founder
effect for this mutation in the United States, since it has not
been found in any of the European cohorts studied (208).
Similarly, the Ile542Leu mutation was present in four Dutch
kindreds, suggesting a common ancestor as the cause for this
clustering (208), whereas the Met398Thr mutation seems to
have a broader range of occurrence. This mutation has been
found in kindreds from Germany and a patient from Sicily
(208), in an FMPP kindred and a patient from the United
Kingdom (191) and in an FMPP patient from Japan (205).
FIG. 6. Mutations in the FSH receptor
protein. Schematic structure of the FSH
receptor protein and localization of the
inactivating (open squares), and one ac-
tivating (filled circle), mutations cur-
rently known in the human FSH recep-
tor. The short lines across the amino
acid chain separate the 10 exons. For
references, see Table 3.
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TABLE 3. Gonadotropin receptor gene variants and mutations





CTGCAG LQ No change (186–188)
Intron 1
(nucleotide 28)
Base Change G7C No change –b g
Exon 8 Silent C610TA7TTA Leu204 –b g
Exon 10 Missense AA872T7AGT Asn291Ser No change (188, 190)
Exon 10 Missense AA935T7AGT Asn312Ser No change (188, 190)









LLKLLLLLQ Inactivating (g, 192)
EC domain
Exon 5
Missense T391GT3CGT Cys131Arg Inactivating (193)
EC domain
Exon 7
Missense T580TC3GTC Phe194Val Inactivating (194)
EC domain
Exon 8
Deletion Dexon 8 Inactivating (195)
EC domain
Exon 10
Deletion Dexon 10 Inactivating (24)
EC domain
Exon 11
Missense T1027GT3AGT Cys343Ser Inactivating c
EC domain
Exon 11
Missense G1060AA3AAA Glu354Lys Inactivating (196)
TM4 Nonsense TGG14733TGA Trp491* Inactivating g
TM5 Missense T1627GT3CGT Cys543Arg Inactivating c
TM5 Nonsense TGC16353TGA Cys545* Inactivating (197)
IL3 Nonsense C1660GA3TGA Arg554* Inactivating (198)
TM6 Missense G1777CC3CCC Ala593Pro Inactivating (199, 200)
TM7 Deletion DC1822TGGTT DLeu608Val609 Inactivating (201)
TM7 Missense TC1847T3TAT Ser616Tyr Inactivating (195, 198)
TM7 Missense AT1874A3AAA Ile625Lys Inactivating (202)
Activating
mutations
TM1 Missense GC1118C3GTC Ala373Val Activating (203)
TM2 Missense AT1193G3ACG Met398Thr Activating (191, 204–206)
TM3 Missense CT1370C3CGC Leu457Arg Activating (207)
TM5 Missense A1624TT3CTT Ile542Leu Activating (206)
IL3 Missense GA1691T3GGT Asp564Gly Activating (206, 208)
IL3 Missense GC1703T3GTT Ala568Val Activating (209)
TM6 Missense ATG17133ATA Met571Ile Activating (175, 210)
TM6 Missense GC1715A3GTA Ala572Val Activating (211)
TM6 Missense A1723TC3CTC Ile575Leu Activating (190, 208)
TM6 Missense AC1730C3ATC Thr577Ile Activating (210, 212)
TM6 Missense GA1733T3GGT Asp578Gly Activating (175, 176, 206, 213, 214)
TM6 Missense G1732AT3TAT Asp578Tyr Activating (205, 206, 215)
TM6 Missense GAT17343GAA Asp578Glu Activating (216)
TM6 Missense G1732AT3CAT Asp578His Activating (217)





Missense A919CT3GCT Thr307Ala No change (218–221)
EC domain
Exon 10
Missense GT1022G3GCG Val341Ala No change (218)d





Missense AT479T3ACT Ile160Thr Inactivating (222)
EC domain
Exon 7
Missense GC566A3GTA Ala189Val Inactivating (220)
EC domain
Exon 7
Missense AA572T3ATA Asn191Ile Inactivating (223, 224)
EC domain
Exon 9
Missense GA671T3GTT Asp224Val Inactivating (225)
TM2 Missense G1255CC3ACC Ala419Thr Inactivating e
IL3 Missense C1717GC3TGC Arg573Cys Inactivating (222)
TM6 Missense C1801TC3GTC Leu601Val Inactivating (225)
Activating
mutationf
IL3 Missense GA1700C3GGC Asp567Gly Activating (226)
a EC, Extracellular; TM, transmembrane segment; IL, intracellular loop; EL, extracellular loop.
b Not tested.
c J. W. M. Martens, S. Lumbroso, A. Richter-Unruh, H. G. Brunner, A. P. N. Themmen, and Ch. Sultan, unpublished.
d Rare polymorphism.
e E. Docherty, P. Pakarinen, A. Tiitinen, A. Kiilavuori, I. Huhtaniemi, S. Forrest, and K. Aittoma¨ki, unpublished.
f The constitutive activity of this mutation has been disputed; see text.
g A. Richter-Unruh, J. W. M. Martens, M. Verhoef-Post, W. A. Kors, G. H. G. Sinnecker, A. L. Boehmer, S. L. S. Drop, S. P. A. Toledo,
H. G. Brunner, and A. P. N. Themmen, unpublished.
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Interestingly, the latter mutation exhibits incomplete pen-
etrance, since one of four carriers of the Met398Thr allele was
unaffected (191), indicating that other factors may affect the
FMPP phenotype.
Some of the amino acid changes found in the LH receptor
in FMPP patients involve a major change in amino acid type
(Table 3), e.g., Asp578Gly involving change from a large
charged to a small uncharged amino acid residue, while in
other patients, more conserved alterations were found, e.g.,
the changes from isoleucine to leucine at codons 542 and 575.
All activating LH receptor mutations are situated in the cy-
toplasmic halves of the transmembrane segments or in the
third intracellular loop (Fig. 5). In some cases, the amino acid
change may involve increased or activating interaction with
the Gs protein, while other residues may be important for
interactions between the different transmembrane segments.
Recently, Abell et al. (236) showed that a synthetic peptide
containing a part of the cytoplasmic half of TM6 including
the Asp578Gly mutation, has Gs stimulatory activity, whereas
a peptide containing the WT residue does not. A TM6 peptide
containing the isoleucine-to-leucine mutation at codon 575
had a similar effect. These results suggest direct interactions
between some of the changed amino acids and the Gs pro-
tein, although the results are also consistent with a theoretical
model of this part of the LH receptor in which the activating
mutations perturb specific interactions of TM6 with TM5 and
TM7 that are critical for stabilizing the inactive state of the
receptor (237). Recently, another molecular model was built
of the LH receptor, which has been used to compare several
different activated and inactivated LH receptor mutants
(238). The model indicates that in activated mutants a crevice
is opened that is formed by IL-2 and -3 and the cytosolic
extensions of TM3, -5, and -6. This crevice, which may allow
G protein interaction with otherwise buried amino acid res-
idues, is closed in inactive LH receptor mutants (238). The LH
receptor conformations with a closed or opened crevice, re-
spectively, may represent the R and R* states, which have
been proposed in models for other G protein-coupled recep-
tors, such as the constitutively active forms of the b2-adren-
ergic receptor (239).
The relationship between cAMP as a second messenger of
hCG binding to the LH receptor and the level of stimulation
of testosterone production has been addressed mostly in in
vitro studies with rodent Leydig cells. Leydig cell testoster-
one production proved to be much more sensitive to LH or
hCG than hormone binding or cAMP levels would suggest.
However, careful examination of adenylyl cyclase activity,
cAMP levels, protein kinase A activation, in addition to spe-
cific inhibitory cAMP analogs, showed that as a result of
intracellular amplification by the signaling cascade from hor-
mone binding to cholesterol side-chain cleavage enzyme ac-
tivity, very small increases in cAMP can give rise to large
increases in steroid hormone production (e.g., see Refs. 240–
244). Thus, the size of the change in the in vitro basal activity
of the mutant LH receptors may correlate with the severity
of precocious Leydig cell activation in the patient in vivo.
Boys that carry the Asp578Tyr mutation show an early onset
of precocious puberty at the age of 1 yr (208, 215, 245), and
the activating effect of the tyrosine substitution was indeed
much stronger than observed with the corresponding glycine
mutant (206). The effect of the type of amino acid substitution
at codon Asp578 appears to be related more to the bulkiness
of the amino acid than its charge or hydrophobicity (216,
246).
Activating LH receptor mutations appear to have no phe-
notype in the female, which may be explained by low or
absent LH receptor expression in prepubertal girls. In addi-
tion, expression of the LH receptor would occur mostly in
theca cells that surround follicles growing independently of
FSH. However, since these follicles probably do not express
high levels of the aromatase enzyme, thecal androgens pro-
duced under the influence of the activated LH receptor are
not sufficiently aromatized to induce puberty. It is also pos-
sible that FSH-evoked paracrine influences from granulosa
cells are needed before the theca cells are capable of active
androgen production in response to LH stimulation (247). In
adult cycling women, the exact timing of the ovulatory LH
peak is an important feature of correct ovarian function, and
expression of an activated LH receptor might have delete-
rious effects on this well regulated system. However, a de-
tailed clinical examination of a female carrier of an Asp578Gly
LH receptor mutation, also the mother of a boy with FMPP,
revealed no infertility or other problems (248). Probably, the
mutation did not activate the receptor beyond the prepu-
bertal level, and the negative feedback systems that regulate
ovarian function were intact (248). Although the activated
FIG. 7. Mutant Met571Ile LH receptor increases basal cAMP-respon-
sive reporter activity. HEK293 cells were cotransfected with a cAMP-
responsive luciferase reporter plasmid (202), a b-galactosidase re-
porter plasmid driven by a constitutive promoter together with the
expression plasmid pSG5 containing the human WT LH receptor
cDNA (open circles) or a human LH receptor cDNA containing the
Met571Ile mutation (closed circles). Cells were incubated with the
indicated concentrations of hCG for 4 h. The luciferase activity in the
cell lysates is presented after normalization for b-galactosidase ac-
tivity as a measure of transfection efficiency. Expression with the WT
LH receptor-expression construct results in a clear response to hCG
with low levels of reporter activity in the absence of hormone. The
Met571Ile LH receptor shows similar response to hCG but with a
substantial increase in basal cAMP-responsive reporter activity.
[Courtesy of Dr. M.Verhoef-Post (unpublished).]
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LH receptors show increased basal activity, the in vitro dose-
response relationships (Fig. 7) indicate that they would still
respond to the high concentrations of LH that are needed to
trigger ovulation.
B. Inactivating mutations of the LH receptor
A special form of complete male pseudohermaphroditism
was described in 1976 in a 35-yr-old 46,XY woman charac-
terized by high LH levels, normal FSH, and extremely low
testosterone (249). LH responded well to GnRH challenge,
whereas FSH increased only marginally. Testosterone in-
creased after ACTH challenge but was completely unrespon-
sive to hCG. The subject had female external genitalia and
two abdominal testes with epididymides and vasa deferen-
tia, but absent Mu¨llerian structures. Upon microscopic ex-
amination, the testes were found to contain seminiferous
tubules with normal appearing Sertoli cells, occasional im-
mature germ cells, but, notably, no Leydig cells (249). Leydig
cell hypoplasia (LCH) or Leydig cell agenesis, as this syn-
drome was named, was reported on several occasions in
prepubertal, adolescent, and adult males (250–254), also in
familial fashion (255–257). Prompted by the lack of hCG
responsiveness, noted in all cases, and by the absence of LH
or hCG binding sites in membrane preparations of removed
testis tissue (258–260), it was hypothesized that Leydig cell
precursors failed to develop, or that Leydig cell differenti-
ation did not occur, as a consequence of aberrant LH receptor
expression or function. Two types of LCH have been pro-
posed (261, 262). The severe form, as described above, is
characterized by complete 46,XY male pseudohermaphro-
ditism, low testosterone and high LH levels, total lack of
responsiveness to LH/hCG challenge, and absent develop-
ment of secondary male sex characteristics. There is a notable
lack of breast development, which is the clearest phenotypic
difference between this condition and androgen insensitivity
(testicular feminization) due to inactivating mutations in the
androgen receptor gene. The milder forms of LCH display a
broader array of phenotypic expression, ranging from mi-
cropenis (261) to severe hypospadias (198). In fact, LCH may
present as a disorder of sex differentiation and virilization
caused by absent or low testosterone production, ranging
from very mild undervirilization to complete pseudoher-
maphroditism, and the relative severity of the phenotype
may depend on the degree of responsiveness to LH/hCG
(see also below).
The poor or totally lacking responsiveness to LH/hCG has
led to the hypothesis that loss-of-function mutations in the
LH receptor gene may be the underlying cause of LCH. Many
different types of mutations may cause full inactivation of
function of the LH receptor gene product. Deletions may
remove large parts of the LH receptor gene and cause com-
plete absence of any LH receptor protein. Otherwise, non-
sense mutations or frameshift-inducing base insertions or
deletions cause premature truncations of the LH receptor
protein and loss of its function. In fact, the first report de-
scribing an LH receptor gene mutation in a LCH kindred
concerned a missense mutation, Ala593Pro, in TM6 near the
extracellular side of the plasma membrane (199) (Table 3).
The homozygous Ala593Pro mutation was found in two
46,XY pseudohermaphrodite adult siblings, born from con-
sanguineous parents, who presented with female external
genitalia, primary amenorrhea, and lack of breast develop-
ment. Their parents were heterozygous for the mutation.
Sections of testicular tissue showed hyalinized seminiferous
tubules with almost total lack of germ cells and very few,
immature type Leydig cells in the interstitium. Transient
expression of the mutated LH receptor in vitro revealed a low
number of hCG binding sites with normal high affinity.
However, when hCG-induced cAMP production was deter-
mined, no effect was detected with the mutant LH receptor,
even at very high hCG concentrations.
Subsequently, an identical homozygous mutation was
found in a 46,XX sister of the 46,XY siblings (200). She pre-
sented with a relatively mild phenotype: amenorrhea with
normally developed primary and secondary sex character-
istics, increased LH and FSH, and low levels of estradiol and
progesterone that were unresponsive to hCG treatment, con-
firming the inactivating mutation in the LH receptor gene.
Histological examination of an ovarian biopsy sample re-
vealed all stages of follicular development, including pri-
mordial follicles and preantral and antral follicles with a well
developed theca cell layer, but no preovulatory follicles or
corpora lutea. In one ovary, a large cyst was present, pre-
sumably a remnant of a nonovulated follicle. Clinical exam-
ination revealed small uterus, normal-sized vagina with hy-
posecretory function and thin walls, and decreased bone
mass, all indicative of low estrogen levels. These observa-
tions strongly support the view that LH is essential for ovu-
lation and sufficient estrogen production, while follicular
development is initially autonomous, and at later stages de-
pendent on intact FSH action. Other similar cases have also
been described, all siblings of 46,XY complete male
pseudohermaphrodites (196, 198, 201).
Additional mutations of the LH receptor, causing LCH in
46,XY patients or amenorrhea in 46,XX patients, have now
been reported (Table 3). As expected, some of these involve
deletions or nonsense mutations. Accordingly, a deletion in
exon 8 causes complete LH receptor dysfunction, both in
terms of absence of binding and absence of signal transduc-
tion (195). Since exon 8 encodes a part of the extracellular
domain, such absence of hormone binding is expected. Par-
tial inactivation of LH receptor function was found in a
patient with a homozygous deletion of exon 10 (24). The
removal of the amino acids encoded by exon 10 from the LH
receptor protein results in inhibited receptor transport to the
plasma membrane and partial obliteration of LH receptor
function (23). In addition, nonsense mutations have been
found in different regions of the transmembrane domain
(TM4: Trp491*; TM5: Cys545*; and IL3: Arg554*) (A. Richter-
Unruh et al., unpublished; 197, 198). These mutations cause
truncation of the LH receptor protein and corresponding
absence of at least part of IL-3 and TM6 and -7, which are
important regions for G protein coupling. Indeed, expression
of the Cys545* LH receptor mutant revealed complete absence
of hormone-induced cAMP production and also very low
hormone binding, probably as a result of misfolding of the
receptor during expression (197). A smaller deletion of
Leu608Val609 (201) in TM7 suppressed severely but incom-
pletely the LH receptor function, as evidenced by a 30-fold
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lower number of plasma membrane LH binding sites after
transient expression of the mutant LH receptor, and only 1.5-
to 2.5-fold increase in cAMP production upon hCG stimu-
lation (201).
Inhibiting mutations have also been identified in the ex-
tracellular domain of the LH receptor. In a compound het-
erozygous subject with LCH (other allele: Cys554*), a 27- or
33-bp insertion (see below) was found between codons 18
and 19 in exon 1 (A. Richter-Unruh, et al., unpublished; 192).
This region contains an imperfect leucine-triplet repeat en-
coding: LQLLKLLLLLQ , insertion site . PPLPRA. A poly-
morphism in the LH receptor gene exists in which CTGCAG
(LQ) is inserted at the same position, without deleterious
effects on receptor function (186–188, 263–265). The partial
gene duplication at this site is probably the result of unequal
crossing over (266) and encodes LLKLLLLLQ (27 bp) or the
same sequence with one additional LQ unit (33 bp), since it
is unknown whether the allele in which the insertion took
place contained the additional polymorphic sequence. The
insertion site is located immediately upstream of the pro-
posed signal peptide cleavage site and may therefore inter-
fere with protein transport to the plasma membrane. In vitro
expression of the insertion mutant showed complete absence
of LH receptor function (192).
The first LH receptor missense mutation in the extracel-
lular domain was found in a patient with incomplete LCH
(193). This Cys131Arg amino acid substitution in exon 5
caused a 95% decrease in hormone binding and a limited
response of adenylyl cyclase to hCG at high hormone con-
centrations. About one third of the interstitial testicular cells
expressed both LH receptor and P450c17 (17-hydroxylase) as
evidenced by immunohistochemical staining, indicating
some residual effect of LH or hCG on the precursor Leydig
cells in this case (193). A homozygous missense mutation
Phe194Val was found in exon 7 of the LH receptor gene (194).
This mutation was located in a stretch of five amino acids
(AlaPhe194AsnGlyThr) that is perfectly conserved in the fam-
ily of glycoprotein hormone receptors. The corresponding
Ala189 of this sequence in the FSH receptor protein has been
found to be mutated in patients with ovarian FSH resistance
(see below; Ref. 220), but functional studies of this mutation
have not yet been reported (194). Located much closer to the
first transmembrane domain and encoded by exon 11, two
amino acid changes have been found, Cys343Ser (J. W. M.
Martens, S. Lumbroso, A. Richter-Unruh, H. G. Brunner,
A. P. N. Themmen, and Ch. Sultan, personal communication)
and Glu354Lys (196), which cause complete inactivation of
LH receptor function. Both Cys343 and Glu354 are conserved
throughout the family of glycoprotein hormone receptors.
The equivalent Glu358 in the rat LH receptor has been ex-
tensively mutated, and it was found that changing this amino
acid to Lys causes low expression and inhibition of signal
transduction (267, 268).
Since quite a number of mutations have been identified in
the LH receptor gene, a comparison can be made between the
extent of the phenotype of LCH patients and the residual, if
any, activity of their LH receptor alleles, similar to the effect
of activating amino acid substitutions in FMPP. Presence of
the Ala593Pro mutation on both alleles or compound het-
erozygosity of the Cys343Ser and Cys543Arg mutations, all of
which completely inactivate the LH receptor, is associated
with complete pseudohermaphroditism (199) (J. W. M. Mar-
tens, S. Lumbroso, A. Richter-Unruh, H. G. Brunner, A. P. N.
Themmen, and Ch. Sultan, personal communication). Trun-
cation of the LH receptor protein in patients homozygous for
a nonsense mutation causes a similar phenotype (197, 198).
A carrier of a homozygous mutant LH receptor that is se-
verely but not completely affected in its activity, such as the
Cys131Arg LH receptor mutant, has a micropenis with hy-
pospadias (193). In contrast, patients homozygous for mu-
tations that cause even less complete impairment of LH re-
ceptor function, such as Ser616Tyr (198) and Ile625Lys (202),
show a mild phenotype (micropenis). Interestingly, the same
Ser616Tyr mutation in combination with a deletion of exon 8
on the other LH receptor allele results in a much more severe
phenotype (perineoscrotal hypospadias) in line with the ex-
pected lower residual receptor activity (195). These correla-
tions of patient phenotype with receptor behavior in vitro
emphasize that there is no clear distinction between complete
and partial feminization of external genitalia in patients with
LCH as proposed previously (262, 269, 270). It will be of great
interest to study the phenotype of 46,XX siblings of patients
with a mild form of LCH, to determine whether reduced, but
not totally absent, LH signal transduction also causes prob-
lems with ovarian function.
Not much is known about the molecular effects of the
mutations on LH receptor function. Although in some cases
G protein coupling itself may be affected, such as in cases of
receptor truncation in which the G protein coupling domain
is absent, other causes of decreased receptor activity may be
caused by lack of transport from the endoplasmic reticulum
or the Golgi apparatus, accompanied by incorrect processing
such as N-linked glycosylation and/or palmitoylation. Some
studies have started to address these details of the receptor
function. Deletion of Leu608Val609 in TM7 causes 80% of the
LH receptor molecules to be retained inside the cell, com-
pared with 40% of the WT receptors in this study (201).
However, although the receptors expressed at the cell surface
bound hCG with similar affinity as the WT LH receptor, their
ability to activate cAMP production was severely reduced
(201). A comparison of the effect of the Ser616Tyr, Ile625Lys
and Ala593Pro mutations on LH receptor function showed
very different results (202). All three mutant receptors
showed much decreased cell surface expression, and their
signaling capacities were compared with the WT LH receptor
expressed at similar receptor densities. The Ala593Pro LH
receptor completely lacked hormone-dependent signaling
activity and was expressed at a very low level (200, 202). The
Ser616Tyr LH receptor hardly displayed signaling, and the
affected receptor activity in the patient appeared to be caused
chiefly by the low level of expression. In contrast, although
expressed at a higher level, the Ile625Lys LH receptor exhib-
ited severely reduced, but not absent, signaling (202). In most
other reports of inactivating mutations in the LH receptor,
comparisons have been made between level of hormone
binding and receptor activation after in vitro transfection in
a suitable cell line, without investigating the mechanisms
responsible for reduced expression at the plasma membrane
(192, 193, 195, 197, 198).
In males, the phenotype of impaired LH/hCG signaling is
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more severe than in women, showing that LH/hCG is es-
sential for correct sex differentiation and that it is mandatory
for any reproductive function at all. Nevertheless, even in the
complete absence of LH/hCG signaling, some autonomous
Leydig cell function remains, as is exemplified by the pres-
ence of epididymides and vasa deferentia in a LCH patient
with complete absence of LH receptor function (199). At the
time of fetal testicular differentiation, around 8 weeks of fetal
life, Leydig cells start to differentiate and to express the
steroidogenic enzymes necessary for androgen production
(58, 59, 271). Probably, Leydig cells produce some androgens
at this time during development, although they do not yet
appear to express LH receptor and are independent of LH/
hCG. A similar situation has been found in the hpg (272) and
common a-subunit null mutant mice (128) (see below), which
display normal male fetal sex differentiation in the absence
of LH. In the human, however, after this hCG-independent
activity, Leydig cells do express LH receptors and go through
differentiation and proliferation stages that parallel serum
concentrations of hCG (59, 271). In some patients who have
been diagnosed with LCH, no LH receptor gene mutations
have been found, despite DNA sequencing of all 11 exons of
the gene (A. Richter-Unruh et al., unpublished; 273). Other
regions of the gene that regulate correct splicing of LH re-
ceptor pre-mRNA or the level of expression of the LH re-
ceptor protein may be changed in these patients. These pro-
moter/enhancer and intronic DNA sequences are difficult to
investigate in the large LH receptor gene. On the other hand,
diagnosis of LCH is not always unambiguous, since other
possible causes of pseudohermaphroditism such as andro-
gen receptor insensitivity and steroidogenic enzyme alter-
ations have to be excluded before LCH can be established.
Several polymorphisms have been identified in the LH
receptor gene. Base changes in intron 1 and exons 8 and 11
appear to be silent. The other three polymorphic sites cause
a change in the protein product of the gene: insertion of
LeuGln at codon 18, Asn291Ser, and Asn312Ser (Table 3).
However, for none of the polymorphic sites, a modification
of LH receptor function or linkage to phenotype has been
described (Table 3).
C. Inactivating FSH receptor mutations
Few mutations have so far been identified in the FSH
receptor gene (Table 3 and Fig. 6). The paucity of FSH re-
ceptor mutations found in patients may indicate that the
phenotype(s) caused by them may be less clear than the
effects of LH receptor mutations and therefore escape our
attention. Alternatively, a selection mechanism may be op-
erative against FSH receptor gene mutations, perhaps based
on a strong dominant antifertility effect that precludes the
inheritance of the faulty allele. FSH has an important role in
the ovary in follicular maturation and in maintenance of
granulosa cell estrogen production. In the male, FSH regu-
lates Sertoli cell proliferation and differentiation in the im-
mature testis and is proposed to participate in the regulation
of spermatogenesis, assuring that it is qualitatively and
quantitatively normal. Thus, loss-of-function mutations in
the FSH receptor might result in small testes with impaired
spermatogenesis in the male, while in women a phenotype
may be expected to be characterized by low estrogen produc-
tion and infertility as a result of absent follicular maturation,
such as is the case in premature ovarian failure or resistant
ovary syndrome. Conversely, a male carrier of an activating
FSH receptor variant may develop more testicular Sertoli cells
and have large testes (megalotestis), with no other clinical ab-
normalities, while a female carrier might present with over-
stimulation of granulosa cell growth causing ovarian malig-
nancies, a high chance of dizygotic twinning, and premature
menopause as a result of increased selection of growing follicles
accompanied by enhanced rate of primordial follicular recruit-
ment. In line with these notions, the candidate syndromes in
which FSH receptor mutational analysis has been carried out
include premature ovarian failure, gonadal dysgenesis, resis-
tant ovary syndrome, hypergonadotropic hypogonadism,
PCOS (219, 274–276), granulosa cell or Sertoli cell tumors (277–
280), and males with absent or low and aberrant sperm counts
with high FSH levels (221), with megalotestis (224), or with
idiopathic male infertility (218). However, in none of these
conditions have mutations in the FSH receptor gene been
found. These studies did reveal three polymorphisms in exon
10 that cause amino acid alterations (Table 3). However, the
altered FSH receptor protein was fully active, and no linkage
with any of the syndromes studied was noticed (218–221).
In the first successful search for loss-of-function FSH re-
ceptor mutations, advantage was taken of the considerable
enrichment of mutations for certain recessively inherited
disorders in Finland (281). A Finnish population-based study
of hypergonadotropic ovarian dysgenesis revealed upon
linkage analysis a locus termed ODG1 that was associated in
a recessive inheritance pattern with the syndrome (282). Sub-
sequently, the locus was mapped to chromosome 2p (220)
that contained both the LH receptor and FSH receptor genes,
at 2p21 and 2p21–16, respectively (7, 8). On the basis of
phenotype of the patients (absence of follicular maturation)
and that no male pseudohermaphroditism was found in the
families (which would be a sign of LH receptor inactivation),
the FSH receptor gene was chosen as the candidate gene.
Sequencing of the coding regions of the FSH receptor gene
resulted in identification of a missense Ala189Val mutation
that segregated perfectly with the phenotype (220). As noted
above, Ala189 is the first amino acid in a perfectly conserved
stretch of five amino acids in the glycoprotein hormone re-
ceptors (Ala189PheAsnGlyThr) in which also an inactivating
mutation of the LH receptor has been identified (194). The
presence of a Val at position 189 may interfere with the
efficiency of glycosylation, resulting in impaired receptor
trafficking and folding accompanied by a decrease in binding
(21). In fact, the bulk of FSH receptor immunoreactivity in
cells transfected with the mutated receptor cDNA appears to
sequester within the cells (P. Pakarinen, A. Rannikko, P.
Manna, I. Beau, E. Milgrom, M. Misrahi, and I. Huhtaniemi,
unpublished). Scatchard analysis and cAMP stimulation
studies in vitro showed that the Ala189Val FSH receptor mu-
tant has normal binding affinity, and severely reduced
plasma membrane expression and signal transduction (Fig.
8) (220). In fact, taking into account the reduced level of
plasma membrane FSH receptors, the cAMP stimulation per
receptor was roughly normal, but quantitatively insufficient
since the bulk of the receptors were sequestered inside the
October, 2000 GONADOTROPIN AND GONADOTROPIN RECEPTOR MUTATIONS 569
 at Medical Library Erasmus MC on November 28, 2006 edrv.endojournals.orgDownloaded from 
cell. The Ala189PheAsnGlyThr FSH receptor sequence also
contains a consensus N-linked glycosylation signal, which
was found to be mutated (heterozygous Asn191Ile) in a
healthy fertile woman (223, 224). In vitro expression of the
FSH receptor mutant revealed almost complete inactivity,
confirming the importance of this region for the receptor
function (224).
A more detailed description of the phenotype of homozy-
gous female carriers of the Ala189Val FSH receptor mutant
allele (283) showed that these patients were clinically similar
to other patients with ovarian dysgenesis, with totally absent
or poor development of secondary sex characteristics and
high serum levels of FSH and LH. The notable difference was
the presence of ovarian follicles in almost all cases with
verified FSH receptor mutation, consistent with the FSH
independence of primordial follicle recruitment and early
follicular growth and development. In contrast, total absence
of all follicles, including those in primordial stage, was ob-
served in the cases where the FSH receptor mutation could
not be detected. Thus, the FSH receptor mutation phenotype
is distinct from the common form of ovarian dysgenesis as
found in Turner’s syndrome with streak ovaries and absence
of growing follicles (283).
In men, this particular FSH receptor mutation has a less
clear phenotype. A total of five homozygous males were
identified and studied in Finnish families with the Ala189Val
FSH receptor mutation. All men were found to be normally
masculinized with normal circulating testosterone, normal
or slightly elevated LH, moderately elevated FSH, and
slightly to severely reduced testicular volume (164). Two of
the men had fathered two children each. However, all of the
five men studied had abnormal semen parameters ranging
from severe or moderate oligozoospermia to normal sperm
concentration with a low volume and teratozoospermia in
one individual (164). Conspicuously, none of them was
azoospermic. These observations lead to the conclusion that
FSH contributes to testicular size and qualitatively and quan-
titatively normal spermatogenesis. However, in the presence
of normal androgen production, fertility is possible in the
absence of FSH action and unlike suggested previously (dis-
cussed in Refs. 284 and 285), FSH action is not compulsory
for the pubertal onset of spermatogenesis.
The Ala189Val FSH receptor mutation seems to be another
member of the Finnish heritage of genetic diseases and is
unlikely to be found in other populations (219, 276, 286, 287).
Recently, two pairs of compound heterozygous FSH receptor
mutations were described from France in women with pri-
mary or secondary amenorrhea, normal pubertal develop-
ment, and follicular development up to the antral stage (222,
225). Two of the mutations, Ile160Thr and Asp224Val, both
present in the extracellular domain (exons 6 and 9, respec-
tively), caused almost completely impaired FSH binding. In
accordance, cells expressing these receptor mutants showed
no or marginal cAMP response to FSH stimulation. The other
two mutations, Arg573Cys (IL 3) and Leu601Val (TM6), caused
less complete receptor inhibition, displaying clear ligand
binding and a residual 12–24% cAMP response to FSH, as
compared with WT receptor. Localization of receptor protein
by confocal immunofluorescent microscopy confirmed these
findings, showing that the completely inactive receptor pro-
tein was sequestered inside cells, whereas both the WT and
incompletely inactivated receptors were present on the
plasma membrane (Fig. 9). It seems, therefore, that the degree
of FSH receptor inactivation by mutations is largely deter-
mined by the degree of receptor sequestration inside the cell.
However, a very recent study has shown that an Ala419Thr
mutation in the second transmembrane loop of FSH receptor
specifically abolishes signal transduction without marked
effect on ligand binding (E. Docherty, P. Pakarinen, A. Ti-
itinen, A. Kiilavuori, I. Huhtaniemi, S. Forrest, and K. Ait-
toma¨ki, unpublished observation).
Although the FSH receptor mutations described to date
are few, the description of the phenotype in relation to the
severity of effect of the mutation on residual FSH receptor
activity may also indicate a genotype-phenotype relation-
ship, as found for the LH receptor mutations. In patients with
the lowest remaining FSH receptor activity, hypergonado-
tropic primary amenorrhea with hypoplastic ovaries is
found, while in carriers of less affected mutations, there is
secondary amenorrhea with normal sized ovaries and fol-
licular development up to the antral stage, underlining the
essential role of FSH in growth and development of the
ovarian follicles (222, 225, 283). Even the plasma estradiol
and inhibin B levels appeared to correlate with levels of
receptor inactivation, and ovaries of patients with the milder
forms of mutations may respond to high-dose FSH stimu-
lation. Hence, the molecular diagnosis of these rare patients
may help in design of rational treatment for their infertility.
D. Activating FSH receptor mutation
To date, a single activating mutation in the FSH receptor
has been identified (Table 3) (226). A hypophysectomized
male under treatment with testosterone had normal sper-
FIG. 8. Ala189Val mutant FSH receptor does not function in signal
transduction. FSH-stimulated cAMP production of MSC-1 cells trans-
fected with the FSH receptor expression construct. Squares denote
wild type, circles represent Ala189Val FSH receptor mutant, and tri-
angles depict mock-transfected controls. Each batch of cells was co-
transfected with a plasmid expressing bacterial luciferase gene under
a powerful viral promoter, to control for transfection efficiency. The
cAMP production was equalized to a constant amount of luciferase
expression and calculated per 106 transfected cells after a 3-h incu-
bation. [Courtesy of Dr. P. Pakarinen (unpublished).]
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matogenesis in spite of undetectable gonadotropins (224,
226). Usually, androgen treatment alone is not sufficient to
support spermatogenesis in the absence of gonadotropins.
Screening of the transmembrane domain-encoding exon 10
of the FSH receptor gene resulted in identification of a het-
erozygous Asp567Gly mutation located in the third intracel-
lular loop. Mutation of the equivalent Asp564Gly in the LH
receptor causes constitutive activity in FMPP patients (206).
However, the proof of constitutive activity of the Asp567Gly
FSH receptor in vitro did not appear as straightforward as it
was in the case of activating LH receptor mutants. In stan-
dard transient transfection experiments, the mutant FSH re-
ceptor behaved similarly to the WT version, both in the
presence and absence of FSH, although careful examination
of basal receptor activity in experiments employing smaller
amounts of transfected DNA, revealed a 1.5-fold increase in
cAMP production (226). However, the constitutive activity of
the Asp567Gly FSH receptor was disputed in two separate
studies on the role of TM5, TM6, and the intervening third
intracellular loop in receptor activation (27, 288). Thus, the
role of the FSH receptor mutant in the spermatogenetic re-
sponse to testosterone in the hypophysectomized patient
remains unresolved. The FSH receptor is not generally re-
sistant to activating amino acid changes. Construction of the
Leu460Arg mutation in TM3 of the FSH receptor, which is the
equivalent of the Leu457Arg LH receptor mutation identified
in a sporadic FMPP patient (207), resulted in significant con-
stitutive activity (235).
Nevertheless, the relatively mild effects on spermatogen-
esis of complete absence of FSH receptor activation both in
human and mouse (220, 289, 290) raises the question of
whether constitutive FSH receptor activity alone could ex-
plain the phenotype of the hypophysectomized male. In re-
lation to the patient described in this report, it should also be
stated that his circulating testosterone concentration in the
absence of replacement therapy was 4.9–7.7 nmol/liter, i.e.,
5- to 8-fold above the normal castrate range (226). The phe-
notype detected may therefore not be representative of the
role of FSH alone in the maintenance of spermatogenesis in
the absence of LH/testosterone action. Further identification
of other activating FSH receptor mutations in patients is
necessary for resolution of this apparent discrepancy.
VI. Animal Models of Disrupted
Gonadotropin Function
The animal models for overexpression of the gonadotropin
genes, as well as targeted disruption of the gonadotropin
subunit and receptor genes, have been of great importance.
Their phenotypes have corroborated the findings made in
humans, helping to decipher the effects of a specific mutation
in a patient whose phenotype may not always be purely due
to a single genetic change. In addition, in those cases where
a human mutation has not yet been identified, the animal
phenotypes produced will help in prediction of the effect of
such mutations in the human.
A. Gonadotropin overexpression
Both LH and FSH overexpressing transgenic mice have been
produced. These are good models for human conditions with
elevated gonadotropin secretion, which have been considered
to cause both infertility and gonadal tumors (291–293).
Risma et al. (294) produced LH overexpressing mice by
expressing, under control of the bovine a-subunit promoter,
the bovine LHb-subunit containing the 29-amino acid C-
terminal extension of the hCGb subunit gene. This resulted
in LH with a long half-life and about 10-fold increase in
plasma concentration. However, the elevation was only seen
in female mice, apparently due to a functional negative feed-
back loop between the testes and the transgene expression.
The female mice were infertile, ovulated infrequently, main-
tained a prolonged luteal phase, and developed pathological
ovarian changes such as marked enlargement, multiple cysts,
and granulosa and theca-interna cell tumors. In addition, a
FIG. 9. Confocal microscopy of WT and mutated FSH receptor im-
munfluorescence localization in intact and permeabilized cells. Cell
surface expression of WT and mutated FSH receptors. COS-7 cells
were transfected with expression vectors encoding either the WT (a
and b) or the mutated Ile160Thr (c and d) or Arg573Cys (e and f)
receptors. Permeabilized (a, c, and e) or nonpermeabilized (b, d,
and f) cells were incubated with the monoclonal FSHR 323 antibody.
Confocal microscopy was used to study the cellular distribution of
receptors. [Reproduced with permission from I. Beau et al: J Clin
Invest 102:1352–1359, 1998 (222). © Journal of Clinical Investiga-
tion.]
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subset of the mice displayed renal abnormalities. The ovarian
tumorigenesis supports some other transgenic models on
tumor promoter effects of high gonadotropin levels (295–
297). This feature may be related to the structural relationship
of gonadotropins with cystine-knot growth factors, includ-
ing nerve growth factor, transforming growth factor-b, and
platelet-derived growth factor-a (6). This would possibly
entail activation of other signal transduction pathways than
that employing cAMP, as has been recently demonstrated
with an activating LH receptor mutation detected in Leydig
cell tumors; the IP3 pathway was preferentially stimulated
by the mutated LH receptor (217). On the other hand, chron-
ically elevated cAMP levels may also provide a tumorigenic
signal, as seems to be the case in the function of constitutively
activated TSH receptors in toxic thyroid nodules (298).
The elevated LH levels appeared to prolong the life span
of corpora lutea in pseudopregnancy-like fashion. The de-
velopment of multiple cysts and increased LH/FSH and
androgen/estrogen ratios are akin to changes seen in human
PCOS. The LHb overexpressing mouse thus clearly demon-
strates that pathologies of ovarian function are associated
with chronically elevated LH levels, which to a certain extent
resemble analogous conditions in the human, i.e., the PCOS
and postmenopausal ovarian stromal tumors.
In males, the transgene did not increase LH levels but,
nevertheless, for unknown reasons, reduced their fertility
and testis size. It remains to be seen what phenotypic ex-
pression chronically elevated gonadotropin levels would
cause in the male. It also is unclear how well these animals
with pharmacologically elevated gonadotropin levels are
able to simulate human conditions with much lower eleva-
tion in gonadotropin concentrations, or mild constitutive
activation of the LH receptor function through mutation.
Kumar et al. (290, 299–302) have produced mice with both
absent and enhanced FSH action and studied their specific
effects on mouse phenotype, as well as explored their con-
tribution to gonadal tumorigenesis of inhibin-deficient mice.
FSH overexpressing male mice had normal testicular differ-
entiation and spermatogenesis. Nevertheless, they were in-
fertile, possibly due to some behavioral effects, functional
incompetence of the sperm, or abnormal secretory products
of the enlarged seminal vesicles (302). Interestingly, these
mice presented with elevated testosterone production and
enlarged seminal vesicles secondary to elevated androgens,
demonstrating that supraphysiological FSH levels somehow
stimulated Leydig cell function, possibly through a Sertoli
cell paracrine factor (303). Whether a gain-of-function mu-
tation of the FSH receptor gene would produce a similar
phenotype in human remains to be seen. With the present
knowledge this seems unlikely, since men with pituitary
adenomas secreting large amounts of FSH have no testicular
phenotype (304).
The transgenic FSH overexpressing females also were in-
fertile, with highly hemorrhagic and cystic ovaries and ele-
vated serum testosterone, estradiol, and progesterone. The
latter may have caused the kidney and urinary tract abnor-
malities observed in these animals which, interestingly, were
also found in LH-overproducing mice (294). No gonadal
tumors were found in these mice, indicating that FSH alone
is not oncogenic. The infertility was due to disrupted fol-
liculogenesis and development of ovarian cysts. Thus, they
mimicked the human ovaries observed in hyperstimulation
and PCOS. Likewise, women with elevated serum FSH lev-
els, in conditions such as postmenopausal ovarian cancer
(305), ovarian hyperstimulation syndrome (306), and with
FSH-secreting pituitary adenomas (307), present with cystic
and hemorrhagic ovaries. Interestingly, the female pheno-
types of the FSH and LH overexpressing mice are very sim-
ilar (see above). The human equivalent to this condition, i.e.,
activating FSH receptor mutation in women, remains to be
characterized.
The same authors (297) have created inhibin-deficient mice
that develop gonadal sex cord-stromal tumors and cancer
cachexia-like syndrome. These mice have been cross-bred
into the FSH-overexpressing and FSH-deficient genetic back-
grounds, which has provided the opportunity to study the
role of this gonadotropin as a contributing factor in gonadal
tumorigenesis (302). Since gonadotropins have also been
suggested to play a role in human ovarian tumorigenesis
(291, 308), these double mutant mice are a useful model for
this human malignancy. The tumorigenesis was delayed and
the cachexia-like syndrome was prevented in the FSH/
inhibin-deficient mice, apparently because of lower activin A
levels. It was concluded that FSH is not a direct causative
factor of gonadal tumors, but is an important trophic mod-
ifying factor. A similar role for LH has been proposed on the
basis of another transgenic mouse model that expresses the
SV40 T-antigen under inhibin a-subunit promoter (295, 296,
309–311). These mice also develop ovarian and testicular
somatic cell tumors, whose growth is dependent on LH. It is
therefore feasible that gonadal tumorigenesis could be as-
sociated with activating mutations of gonadotropin receptor
genes, but, obviously, such cases would be extremely rare.
B. Targeted disruption of gonadotropin genes
A classical, naturally occurring knockout of gonadotropin
secretion is the hypogonadotropic hpg mouse (312), due to
a long deletion in the GnRH gene. GnRH synthesis and
secretion are totally abolished in these mice, and there is a
consequent near-total deficiency of FSH and LH. This mouse
mutant has been extensively used as a model with which to
study the phenotypic expression of hypogonadotropic hy-
pogonadism and for its experimental treatments.
Targeted disruption (knockout) of the a-subunit (128) and
FSHb (290) genes have been produced, but that of LHb has
not yet been reported. Genetic disruption of the a-subunit
gene caused, as expected, hypogonadal and hypothyroid
phenotype resulting in dwarfism. Thyroid development of
the animals was arrested in late gestation, and gonadal de-
velopment was arrested several weeks after birth. GnRH
neuron migration, development of secondary sex organs,
and gonadal development during the fetal and neonatal pe-
riods were normal.
Hypothyroidism of the mice was an expected finding, and
a more intriguing finding concerned effects of lack of go-
nadotropins. It was found that in both sexes, the sexual
differentiation proceeded normally until birth. This finding
strengthens the contention that gonadotropin action, at least
in the rodent, is not needed in utero. Earlier studies have
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demonstrated that, whereas female sexual differentiation
seems to occur without influence of the fetal ovary, the male
sex organ differentiation is critically dependent on the two
hormones produced by the fetal testis, i.e., testosterone and
AMH. In adult testis, testosterone production is critically
dependent on LH action. It seems that neither of the pituitary
gonadotropins, secreted already in utero, is needed for fetal
testicular activity. In fact, it was shown recently that in rat
fetuses, the testicular testosterone surge on days 17–18 of
fetal life precedes the appearance of LH in circulation (313),
and male sexual differentiation of hpg mice is also normal
despite near-total lack of gonadotropins (312). A great num-
ber of paracrine factors, ineffective in adult testis, are able to
stimulate fetal testicular steroidogenesis (313). Hence, the
rodent fetal testes seem to be able to produce testosterone
and AMH without gonadotropins, as was clearly demon-
strated by the common a-subunit null mutant mice (128).
Male sexual differentiation seems to occur normally even in
mice with disrupted thyroid-specific enhancer-binding pro-
tein (T/ebp) (314), born without the pituitary gland (P. Pa-
karinen, F. El-Gehani, S. Kimura, L. J. Pelliniemi, and I. Hu-
htaniemi, unpublished data). The situation in humans may
be somewhat different, due to the presence of hCG, known
to be able to stimulate fetal testes (59). Since the single LH-
deficient human male so far described was normally mas-
culinized at birth (118), hCG was apparently sufficient to
stimulate his testicular steroidogenesis in utero. However,
also in the human there is some LH/hCG-independent fetal
Leydig cell function, as indicated by the presence of epidid-
ymides and vasa deferentia in the patients with complete
LCH (see Section V.B).
The FSH-deficient female mice produced by disruption of
the FSHb gene with the embryonic stem cell technique (290)
are infertile due to a block in folliculogenesis before antral
follicle formation. The phenotype of these mice is very sim-
ilar to a respective model with disrupted FSH receptor func-
tion (289, 315) and the human cases with inactivating mu-
tation in the FSHb subunit (123, 124, 126) or the FSH receptor
(220) genes. All female mice were infertile, and upon histo-
logical examination, their ovaries were small and thin, lack-
ing corpora lutea and failing to show follicular development
beyond the preantral stage. As a sign of ovulatory compe-
tence, PMSG/hCG treatment and mating of the knockout
mice resulted in normal rate of superovulation and two-cell
embryos. Unlike males, the females had elevated LH levels,
apparently due to sex differences in feedback regulation. All
data on genetic inactivation of FSH action thus agree on the
crucial role of FSH in female fertility, due to its action during
the final stages of follicular maturation and antral follicular
formation.
In males, much milder phenotypic effects were seen. The
knockout males were normally masculinized and fertile, al-
though their testes were reduced in size. Again, the pheno-
type of the males was very similar to the phenotype of the
FSH receptor knockout males (289, 315) and of men with FSH
receptor defect (164). The apparent discrepancy with the two
men with confirmed inactivating mutations in the FSHb gene
were discussed above. In the FSHb knockout mice, the total
seminiferous tubule volume was reduced, apparently due to
ineffective proliferation of Sertoli cells in the prepubertal age
because of lack of FSH (316). The Leydig cell number, as well
as LH, testosterone, and accessory sex gland weights were
normal, indicating that the putative FSH-dependent Sertoli
cell factor, suggested to stimulate Leydig cells (303), is phys-
iologically of minor importance. In keeping with the sup-
pressed spermatogenesis, although adequate for fertility,
was the finding of 75% lower epididymal sperm numbers,
lower proportion of motile sperm, but normal viability.
Hence, this model clearly demonstrates that FSH is needed
for normal testicular size and quantitatively and qualita-
tively normal spermatogenesis, but not for spermatogenesis
or male fertility per se.
C. Targeted disruption of gonadotropin receptor genes
In contrast to the many animal models that have been
developed to investigate the direct role of gonadotropins, the
only mouse model directed toward gonadotropin receptor
function is the FSH receptor null mutant mouse (289, 315). To
date, no mice with disrupted LH receptor (or LH) function
have been reported. Likewise, the models for constitutive LH
or FSH activation are missing. The FSH receptor null mutant
mice in the two existing reports were developed using ho-
mologous recombination strategy with a mouse genomic
DNA construct in which exon 1 of the FSH receptor was
replaced by a marker gene. The absence of FSH receptor was
verified by Northern blotting and FSH binding experiments.
Female FSH receptor null mice were infertile and showed
thin uteri caused by low estrogen production by the small
ovaries, with blockade of follicular development at the pre-
antral stage. No Graafian follicles or corpora lutea could be
identified.
Male FSH receptor null mice were fertile, but had small
testes and decreased testosterone levels. Semen analysis
showed a decrease in the number and motility of sperm, and
a relative increase in aberrant spermatozoa, such as bent tails
and cytoplasmic droplets. The decrease in testis size ap-
peared to be caused by a decrease in seminiferous tubule
volume, although a decrease in tubule length, which would
be caused by a decrease in Sertoli cell number, was not
excluded. FSH levels were increased in both male (3-fold)
and female animals (15-fold), accompanied by a significant
enlargement of the anterior lobe of the pituitary gland with
a high number of FSH producing cells.
In many respects, the FSH receptor null mutant mice ap-
pear to be a complete phenocopy of the human patients with
inactivating FSH receptor mutation described above (164,
220, 283): incomplete suppression of spermatogenesis with
increased proportion of aberrant forms of spermatozoa and
a blockade of follicular development, but intact primordial
follicle recruitment. However, some intriguing and unex-
plained observations were made in the mice that have not
been described in human patients. First, the inhibin-medi-
ated feedback appears to be altered in FSH receptor null
mutant mice. FSH was increased strongly in females, al-
though no change in immunoreactive inhibin was found. In
the males, however, inhibin was decreased with only a slight
elevation of FSH. Furthermore, heterozygous females had
unchanged FSH levels, but showed an intermediate pheno-
type, indicating that the expression level of the FSH receptor
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in these animals is not under strict regulation, but rather is
dependent on gene dosage. Heterozygous males also dis-
played an intermediate phenotype with respect to the effect
on FSH and testosterone levels. Interestingly, in the FSH null
mutant mouse model, such a difference between heterozy-
gous and WT animals has not been noted (290). Lastly, in
spite of the absent antral follicular development, anovula-
tion, and decreased estrogen levels, vaginal smears of the
mice still showed a periodic estrous cycle with a recognizable
estrus every 4 days (289). This was not observed in another
FSH receptor knockout model, where all homozygous mu-
tant females were anestrous, with imperforate vaginas (315).
VII. Future Directions
Human mutations for most of the gonadotropin ligand
and receptor genes are already known. Of the possible per-
mutations, the largest number of cases have been reported
for the activating and inactivating LH receptor mutations,
and their phenotypic expression is now relatively well char-
acterized. Only one male with inactivating LHb mutation has
so far been reported (118). Although the phenotype of this
subject is clear and is apparently in line with the known
actions of LH at the different times of development, addi-
tional cases with similar mutation would strengthen our
knowledge about LH action. It would also be intriguing to
study women with similar mutation, which should elucidate
the role of LH and LH receptor, if any, in the fetal period of
female development. Likewise, mouse models of disrupted
LH synthesis, as well as activating and inactivating LH re-
ceptor function, still remain to be reported. There is a trans-
genic mouse overexpressing LH, but in this particular strain,
only the females are hypergonadotropic (294). Therefore, the
phenotype of male mice with LH overproduction still re-
mains to be characterized.
As for the consequences of mutations in FSH and FSH
receptor genes, much less is still known. Three females and
two males with mutated FSHb gene have been reported
(123–127, 162). The female cases all display the expected
lack of follicular development that was successfully
treated with gonadotropins. The findings are identical to
the inactivating FSH receptor mutations and the FSHb and
FSH receptor null mice, and therefore the role of FSH in the
female can be considered quite well explored. However,
there is a clear discrepancy between the consequences of
FSH receptor or FSHb mutations in men (125, 127, 162,
164). Five men reported with the FSH receptor mutation
have at least some spermatogenic activity, whereas the
two men with disrupted FSHb function are azoospermic.
It is apparent that more men with both mutations must be
studied before the final word about the absolute or relative
necessity of FSH for spermatogenesis is said. This question
is of practical importance in view of the ongoing trials of
FSH treatment in idiopathic male infertility and the
prospects of FSH elimination as a strategy of male
contraception.
Some polymorphisms have been detected in genes of the
gonadotropins and their receptors. Their impact on pituitary-
gonadal function is still largely unexplored. Somewhat more
is known about a common polymorphism detected in the
LHb gene (see above, Section IV.C), which seems both to
predispose and protect its carriers from various pathologies
of pituitary-gonadal function, such as PCOS, infertility, and
breast carcinoma. The phenotypic expression of this poly-
morphism seems to vary between different populations,
which may be a general phenomenon concerning polymor-
phisms. It is likely that additional polymorphisms will be
found both in genes of the gonadotropins and their receptors,
and they are likely to provide further explanations for the
wide individual variability observed in reproductive func-
tions.
The finding of activating TSH receptor mutations in thy-
roid adenomas suggested that such mutations in the LH and
FSH receptors might have similar tumorigenic effects. Con-
stitutive activation of the cAMP pathway by activating mu-
tations in Gsa [gsp mutation (317)] has been found to be
oncogenic in human ovarian stromal and testicular Leydig
cell tumors (318), but no association has been indicated be-
tween FMPP and Leydig cell adenoma, suggesting that in-
creased cAMP levels are not necessarily oncogenic. Recently,
an activating LH receptor mutation (D578H) was identified in
Leydig cell adenoma specimens from three boys (217). This
particular LH receptor mutation has the special characteris-
tic, not found in other mutants, that it not only causes high
levels of cAMP in the absence of ligand, but also causes
constitutive coupling to the IP3 pathway, suggesting that this
coupling, by itself or through synergism with the cAMP
pathway, is essential to the tumorigenic activity of this mu-
tation. However, the increased activation of the IP3 pathway
may also be symptomatic for persistent activation of alter-
nate G protein-mediated signal transduction pathways that
have been shown to activate proliferation, e.g., through ac-
tivation by b-g subunits (319–321). Possibly, a different mode
of G protein activation may also be operative in the onco-
genic action of the gsp mutation and explain why increased
cAMP levels induced by mutant LH receptors do not cause
Leydig cell adenomas, whereas the gsp mutation does. By
and large, it will be interesting to address the possible specific
roles and interactions of the different signal transduction
systems in the overall actions of gonadotropins.
Recently, an FMPP patient with testicular seminoma
was reported (322). The occurrence of these relatively rare
disorders could be attributed to chance but could also be
the effect of continuous stimulation by increased levels of
androgens. The significance of the finding of Leydig cell
adenoma and testicular seminoma in FMPP patients may
become more apparent when more patients have been
described. Although quite extensive studies have been
carried out, no FSH receptor mutations, activating or in-
activating, have been identified in granulosa cell or Sertoli
cell tumors (277–280). The tumor-promoting potential of
high FSH and LH levels has also been suggested by the
inhibin peptide knockout models (297), the SV 40 T-anti-
gen-expressing transgenic mice (295), and mice overpro-
ducing LH (294). The potential tumorigenicity of gonad-
otropins and their molecular mechanisms need to be
addressed in more detail.
The recent discovery of gonadotropin receptor expression
in extragonadal tissues (86) still remains without explana-
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tion. All phenotypes observed with respect to human go-
nadotropin receptor mutations are related to specific gonadal
expression, suggesting that extragonadal gonadotropin ef-
fects are unlikely to be of major physiological significance.
Possibly, extragonadal LH receptor expression is caused by
illegitimate or “leaky” transcription, which is detected by the
very sensitive PCR methods that are often applied in these
studies. The LH receptor knockout mouse model will prob-
ably be pivotal in solving this controversy. Mouse transgenic
models will also be important in elucidating the importance
of the multiple mRNA splice variants that are known to exist
for the gonadotropin receptor genes (323–335).
Although the physiology and pathophysiology of gonad-
otropin function was previously characterized by classical
physiological and biochemical research methods, novel in-
formation brought by recent molecular approaches has elu-
cidated totally new aspects of these regulatory mechanisms.
All is not yet known; on one hand, the research of importance
of the genetic variability of gonadotropin action and, on the
other hand, novel genetically modified animal models, will
undoubtedly unravel totally new features of gonadotropin
functions.
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